Loyola University Chicago

Loyola eCommons
Chemistry: Faculty Publications and Other
Works

Faculty Publications and Other Works by
Department

9-23-2010

Orally Active MMP-1 Sparing α-tetrahydropyranyl
-tetrahydropyranyl and α-piperidinyl
-piperidinyl
Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy
in Cancer, Arthritis, and Cardiovascular Disease
Daniel P. Becker
Loyola University Chicago, dbecke3@luc.edu

Thomas E. Barta
Louis J. Bedell
Terri L. Boehm

Follow this and additional works at: https://ecommons.luc.edu/chemistry_facpubs
Part of the Chemistry Commons

Author Manuscript
This is a pre-publication author manuscript of the final, published article.
Recommended Citation
Becker, Daniel P.; Barta, Thomas E.; Bedell, Louis J.; and Boehm, Terri L.. Orally Active MMP-1 Sparing αtetrahydropyranyl and α-piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in
Cancer, Arthritis, and Cardiovascular Disease. Journal of Medicinal Chemistry, 53, 18: , 2010. Retrieved
from Loyola eCommons, Chemistry: Faculty Publications and Other Works, http://dx.doi.org/10.1021/
jm100669j

This Article is brought to you for free and open access by the Faculty Publications and Other Works by Department
at Loyola eCommons. It has been accepted for inclusion in Chemistry: Faculty Publications and Other Works by an
authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
© 2010 American Chemical Society

Orally-Active MMP-1 Sparing α-Tetrahydropyranyl and αPiperidinyl Sulfone Matrix Metalloproteinase (MMP)
Inhibitors with Efficacy in Cancer, Arthritis, and
Cardiovascular Disease

Daniel P. Becker,* Thomas E. Barta, Louis J. Bedell, Terri L. Boehm, Brian R. Bond,§ Jeffery
Carroll, Chris P. Carron,⊥ Gary A. DeCrescenzo, Alan M. Easton, Chris L. Funckes-Shippy,
Marcia Heron, Susan Hockerman, Susan Carol Howard, James R. Kiefer,‡ Madeleine H. Li,
Karl J. Mathis, Joseph J. McDonald, Pramod P. Mehta, Grace E. Munie, Teresa Sunyer, Craig
A. Swearingen, Clara I. Villamil, Dean Welsch,& Jennifer M. Williams, Ying Yu, Jun Yao
Pfizer Research, 700 Chesterfield Village Parkway, St. Louis, MO 63198, USA

*To whom correspondence should be addressed. Loyola University, 6525 North Sheridan, Chicago, IL 60626,
Phone: 773-508-3089. Fax: 773-508-3086. e-mail dbecke3@luc.edu. §Contact for cardiovascular biology, email
brian.r.bond@pfizer.com.

⊥

Contact for cancer Biology. Current address: Monsanto Company C3NG, 800 N.

Lindbergh Blvd., St. Louis, MO 63167. email chris.p.carron@monsanto.com. ‡Contact for crystallography and
computational chemistry, email grenache-shiraz@att.net.

&

Contact for crystallography and computational

chemistry, email dean.j.welsch@pfizer.com.

a

Abbreviations: ADME, absorption, distribution, metabolism and exctetion; Ar, aryl; Arg,
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Abstract

α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent
inhibitors of MMP’s-2, -9, and -13 that spare MMP-1, with oral efficacy in inhibiting tumor
growth in mice and left-ventricular hypertrophy in rats, and cartilage degradation in vitro. αPiperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication
of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i
(SC-77774), respectively were identified as backup compounds.

Introduction

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that are
involved in the remodeling and degradation of all components of the extracellular matrix (ECM)

and have key roles in development, morphogenesis, bone remodeling, wound healing, and
angiogenesis.1 The first matrix metalloproteinase, a collagenase, was discovered by Gross and
Lapiere in 1962 explaining the metamorphosis of a tadpole into a frog.2, 3 However,
inappropriate MMP activity has been implicated in a number of disease states including tumor
growth and metastasis4-6 degradation of articular cartilage in arthritis7-9 and tissue remodeling
and weakening of the left ventricular wall in congestive heart failure.10-13 In order to ameliorate
disease progression resulting from inappropriate matrix remodeling mediated by MMPs in these
various disease states, MMP inhibitors (MMPi's) have been extensively explored.4, 5, 14-16

However, patients dosed with broad-spectrum MMPi’s including marimastat (1, Figure 1) suffer
stiffening of the joints referred to as musculoskeletal syndrome (MSS)12 and the broad-spectrum
inhibitor marimastat induces joint fibroplasia in rats.17 The underlying cause of MSS observed
clinically with broad-spectrum inhibitors, has been hypothesized to be due to inhibition of the
constitutive interstitial collagenase MMP-1,18-21 or sheddases such as TACE22 or a combination
of those metalloproteinases. Hence, recent efforts have been toward the discovery and
development of highly-specific MMP inhibitors that spare off-target isozymes.23-26

Several MMP inhibitors have been in clinical trials. Bramhall reported the first success in
treating cancer with an MMPi in a placebo-controlled, double-blind study treating gastric cancer
patients with the broad-spectrum inhibitor marimastat (1).27 Marimastat afforded a survival rate
similar to gemcitabine in patients with unresectable pancreatic cancer,28 and a survival benefit
was demonstrated in glioblastoma multiforme patients on marimastat in combination with
temozolomide,29 although results with marimastat have been mixed and plagued with MSS.30
Rebimastat (2, D2163/BMS-275291), a thiol-containing, broad-spectrum MMP inhibitor that does not

inhibit sheddases, was added to systemic chemotherapy for the treatment of hormone-refractory prostate
cancer with bone metastases31 and for Kaposi Sarcoma.32 Encouragingly, rebimastat did not elicit joint
toxicity in Phase I studies at levels well above the targeted therapeutic range. but patients did suffer from
general toxicities and lack of efficacy and the compound was therefore not advanced, In a Phase II earlystage breast cancer trial, the pattern of arthralgia in rebimastat-treated patients was consistent with MMPiinduced joint toxicity, although the differential incidence of arthralgia did not reach statistical
significance.33 A Phase III study of 3 (Prinomastat/AG3340) in non-small-cell lung cancer (NSCLC) did
not show improvement in the outcome of chemotherapy in advanced cancer, and toxicities did include

arthralgia, stiffness, and joint swelling.34 Carboxylic acid 4 (PG-116800) is a broad-spectrum
MMP inhibitor that elicited arthralgia despite sparing both MMP-1 and MMP-7, and the
compound failed to show efficacy in preventing ventricular (LV) remodeling after myocardial
infarction in humans over a course of 90 days of dosing,35 despite impressive outcomes in
preclinical animal studies where it significantly reduced LV volumes along with infarct zone
collagen content in a post-MI porcine model.36 Carboxylic acid 4 also induced musculoskeletal
toxicity without clear benefit in patients with knee osteoarthritis in a 12-month, double-blind
study.37 Despite these setbacks, impressive efficacy in preclinical models combined with
advances in the understanding of MMP biology, improved parameters to adequately evaluate
efficacy, and enhanced inhibitor design underscore the perseverance toward safe and efficacious
MMP inhibitors in the clinical setting.4, 5
We previously described the synthesis and MMP inhibitory activity of β-sulfone
hydroxamates38, 39 inspired by the Roche broad-spectrum MMP-inhibitor 5 which was in the
clinic for OA.40, 41 Our early β-sulfones potently inhibited MMP-2 and MMP-13 while sparing
MMP-1, but suffered poor pk. We subsequently discovered that α-sulfone hydroxamates
including 6 (SC-276) are superior to the β-sulfones in both MMP-1 sparing enzyme profile and

ADME properties, and exhibited excellent oral antitumor efficacy in vivo.42 Hydroxamates tend
to be rapidly metabolized, but we believe that the α-spiro moiety in combination with the αsulfone moiety sterically hinder the metabolism of the otherwise labile hydroxamate moiety in
vivo leading to the outstanding pk properties of molecules of type 6. Herein we highlight our
further efforts in the exporation of α-sulfone α-piperidine and α-THP hydroxamates resulting in
the discovery of potent inhibitors of MMP’s-2, -9, and -13 that spare MMP-1, with oral efficacy
in inhibiting tumor growth in mice, cartilage degradation in vitro, and left-ventricular
hypertrophy in rats, including the development candidate 19v (SC-78080/SD-2590) as well as αpiperidine 19w (SC-77964) and α-THP 9i (SC-77774).
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Chemistry

The preparation of α-sulfone hydroxamates 9a-m and 19a-ee is summarized in the following
schemes. Phenyloxyphenyl α-tetrahydropyranyl sulfone hydroxamate 9a was prepared as
outlined in Scheme 1. 4-Fluorosulfone 7 was reacted with phenol in the presence of cesium
carbonate to afford the diaryl ether followed by saponification to yield carboxylic acid 8a.
Direct coupling with hydroxylamine employing EDC afforded hydroxamate 9a after purification
by reverse-phase chromatography. Other α-tetrahydropyranyl sulfone hydroxamates were
prepared according to Scheme 2. O-Tetrahydropyranyl-protected hydroxamate 10 was
prepared42 by hydrolysis of the methyl ester of 6 with potassium trimethylsilanoate followed by
EDC coupling with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine. Nucleophilic aromatic
substitution of the fluoride proceeded in the presence of cesium carbonate in DMF to afford
THP-protected diaryl ethers 11. Acidic removal of the THP group with HCl afforded the αtetrahydropyranyl hydroxamates 9. Specifically for the preparation of 4hydroxyphenyloxyphenyl 9e, the phenol employed was 4-(benzyloxy)phenol yielding 11e [Ar =
4-(benzyloxy)phenyl], which was deprotected as well as debenzylated with concentrated HCl in
glacial acetic acid at 60°C to afford 9e.

Scheme 1. Preparation of α-tetrahydropyranyl-α-sulfone 9a

Scheme 2. Synthesis of α-tetrahydropyranyl-α-sulfones 9b-d, f-h, j-m

The preparation of α-tetrahydropyranyl sulfone hydroxamate 9i bearing the 4-trifluoromethyl
group commenced with diaryl ether 12 (Scheme 3). According to the general method of
Samaritoni,43 phenol 12 was deprotonated with sodium hydride and the resulting sodium salt was
then treated with dimethylthiocarbamoyl chloride. Pyrolysis and subsequent hydrolysis afforded
thiophenol 13, which was alkylated with sodium chloroacetate and oxidized with potassium
peroxymonosulfate to yield sulfone 14. Fischer esterification was followed by double alkylation
with bis(2-bromoethyl)ether and hydrolysis with potassium trimethylsilanoate to afford

carboxylic acid 8i. Coupling with THP-protected hydroxylamine was accomplished with the
water-soluble diimide reagent (EDC) to afford the protected hydroxamate 11i, which was
deprotected with HCl in 1,4-dioxane to afford hydroxamate 9i.

Scheme 3. Synthesis of α-tetrahydropyranyl-α-sulfone 9i

The N-unsubstituted α-piperidines 19j, p, and u were prepared as summarized in Scheme 4. NAryl fluoride 15 was subjected to nucleophilic aromatic substitution with the requisite phenol
(ArOH) with cesium carbonate to afford the corresponding diaryl ether 16. Saponification of the
ethyl ester of 16 gave carboxylic acid 17j, and coupling with tetrahydropyranyl-protected
hydroxylamine using EDC gave the protected hydroxamate 18. Removal of both the BOC and
the tetrahydropyranyl protecting groups afforded α-piperidine hydroxamates 19.

Scheme 4. Synthesis of unsubstituted α-piperidine hydroxamates 19j,p,u
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Scheme 5 outlines the general synthesis of N-substituted α-piperidine sulfonamide hydroxamates
19. N-BOC ethyl ester diaryl ether 16 was deprotected with trifluoroacetic acid to afford the
secondary amine, which was then alkylated or subjected to reductive alkylation to give N-alkyl
piperidines 20.

Saponification then gave carboxylic acids 17 which was coupled with O-

(tetrahydro-2H-pyran-2-yl)hydroxylamine to give the THP-protected hydroxamates 18.
Removal of the THP with HCl gave the free hydroxamate as the hydrochloride salts 19. For the
specific preparation of N-acetyl trifluoromethoxyphenyloxyphenyl sulfone derivative 19x, NBOC carboxylic acid 17a was deprotected with HCl and then acetylated with acetyl chloride to
afford acetamide 17x, which was then converted to the hydroxamate 19x via the THP-protected
intermediate. Alternatively for the preparation of hydroxamates 19, N-alkylation of piperidine

2142 may be carried out first to afford N-alkylpiperidines 22 followed by nucleophilic
displacement of the aryl fluoride to yield diaryl ethers 20 (Scheme 6) which are then converted to
hydroxamates 19 according to Scheme 5.

Scheme 5. Synthesis of N-alkylated α-piperidine hydroxamates 19a-z

Scheme 6. Alternate synthesis of N-alkylated α-piperidine ethyl esters 20a-bb

Results and Discussion

The synthesized α-tetrahydropyranyl (THP) and α-piperidine hydroxamates were tested for
inhibitory potency versus MMP-1, -2, -3, -7, -8, -9, -13 and -14 (Tables 1 and 2, respectively).
Selected analogs were assayed for pharmacokinetic profiles in rats to assess potential for further
development. Rats metabolize hydroxamates quite rapidly, so using the rat as a filter was a high
bar that we expected would improve the quality of compounds selected for advancement within
the series. Moreover, the post-MI left-ventricular hypertrophy efficacy assay was performed in
the rat (vida infra) and therefore it was essential to have good oral exposure in this species. As
noted above, the α-spiro, α-sulfone moiety that was optimized in our earlier work42 was
maintained because of its beneficial effect on pharmacokinetic properties of the analogs,
apparently through sterically limiting access to the hydroxamate by metabolic enzymes, in
addition to improving enzyme potency and selectivity.

Intermediate carbylic acid of all

hydroxamates were also tested but failed to show any significant inhibitory potency for the MMP
isozymes tested.
The α-THP series was generally employed for rapidly screening the P1´ (diaryl ether)
moieties for enzyme inhibitory potency and selectivity, since synthesis via common intermediate
10 (Scheme 2) enabled rapid analog production. Most analogs in Table 1 were prepared via this
method. This strategy of rapidly screening α-THP analogs, in some cases employing parallel
medicinal chemistry (PMC), also enabled the discovery of compounds with more selective
enzyme profiles, some of which have now been reported.44, 45 In most cases, the α-piperidines
exhibited greater exposure than the α-THP analogs.

Simple phenyloxyphenyl derivative 9a exhibited subnanomolar potency for MMPs-2, -3,
-9 and -13. Potency for MMP-1 was 268 nM, with selectivity for MMP-13 relative to MMP-1 at
approximately 2700X, but we sought an even wider therapeutic window (>10,000X) with respect
to MMP-1 to avoid any inhibition of this isozyme at Cmax. We had noted previously that the
phenyloxyphenyl ethers were more potent than phenylthiophenyl ethers of type 6, but turned our
attention away from the more metabolically labile thioethers to the oxygen-linked analogs
described herein, relying on aryl substitution on the distal ring to afford greater selectivity.
Unsubstituted phenyl ether 9a had only 5.8% bioavailability in the rat, presumably due to the
availability of the para position in the distal ring to metabolism, combined with the low clogP of
0.8, given the optimal logP for oral bioavilability of ~2,46 which was consistent with our
findings in this series. Thus, our strategy in analog preparation was to improve potency and
selectivity with aryl substituents, and to block metabolism at the 4-position, but given the
narrowness of the P1´ pocket, we were essentially limited to substituents in the 3- and/or 4positions in the distal ring. Substitution with a chlorine on the 3-position (9b) raised the clogP to
1.51, but reduced the potency for all MMP isozymes tested by several fold. Chlorine substitution
on the 4-position (9c), however, maintained robust potency and dramatically enhanced the oral
exposure in rat, giving an excellent bioavailability of 46%, consistent with blocking metabolism
at the electron-rich 4-position of the phenyl ether. Interestingly, hydroxamate 9c is the α-sulfone
analog of β-sulfone 5 that was advanced by Roche Bio-Science to Phase II clinical trials for
osteoarthritis.41 We had directly compared 9c with RS-130,830 (5) in our earlier report to
demonstrate the superiority of α-sulfones over β-sulfones in both potency and pk. 3,4-Dichloro
substitution led to approximately an order of magnitude loss of potency (9d), given the steric
demand of the two chlorine atoms. 3,5-disubstitution with either two chlorines or two methoxy

substituents led to compounds that were much less potent for MMP-13 (83 nM and 230 nM,
respectively; these compounds are not exemplified in the Tables). Introduction of an H-bond
donor/acceptor 4-hydroxy group in phenol 9e gave excellent potency for desired isozymes, but
surprisingly a relatively potent MMP-1 inhibition of 400 nM. As part of our strategy we turned
to ethers of phenol 9e to extend the P1´ substituent even further, while blocking the 4-position
without introducing metabolically-labile benzylic hydrogens. Introduction of the more bulky
isopropyloxy in compound 9f and the biphenyl moiety in 9g gave potent compounds, and
slightly-reduced potency for MMP-1 (>1000 nM) by biphenyl 9g. Installation of a
trifluoromethyl group in the 4-position gave a more selective compound (12,500X for MMP-13
over MMP-1) and modest pk in the rat. Moving the trifluoromethyl group to the para position
improved both potency and selectivity (20,000X for MMP-13 vs. MMP-1) and dramatically
enhanced the pk, with t1/2 = 2.68 h and BA = 33%. Similarly, 4-trifluoromethoxyphenyl ether 9j
was several times more potent, and also exhibited excellent pk in the rat. These two
trifluoromethyl-containing compounds (9i and 9j) had the best overall profiles that we had seen
among the MMP-1 sparing α-THP sulfones, with greater exposures and half lives than 4-chloro
derivative 9c, and rivaling α-piperidine 6 (cf. Table 2). Methylthio derivative 9k also had
excellent potency, as did trifluoromethylthio derivative 9l, which also had a noteworthy pk
profile, boasting a bioavailability of 49%. The latter two compounds were de-emphasized due to
modest concerns that the sulfur linkages might present a metabolic liability, and
trifluormethylthio moiety of 9l raised concerns about a high cost of goods. 4-Pyridine derivative
9m was an order of magnitude less potent at MMP-13 than several other α-THPs, and had low
exposure upon oral dosing in the rat, with a t1/2 of only 0.25 h and the plasma concentration

approaching 0 ng/mL after 6 hours, possibly due to oxidation of the pyridine nitrogen as well as
its dramatically lower clogP of -2.6.
Table 2 summarizes the MMP inhibitory potency and rat pharmacokinetics of selected αpiperidine sulfone hydroxamates. Among these α-piperidines, we employed N-substituted
piperidines of varying basicity with the expectation of optimizing pk through modulating
physicochemical properties and affecting membrane-crossing potential.47 The crystal structure
of (vide infra) showed that the piperidine N-substituent projects into solvent, so this moiety
generally had little impact on potency and selectivity at least for the smaller substituents, and
provided a handle for modulating pk. An N-methoxyethyl substituent lowers the basicity of the
piperidine nitrogen inductively48 and substitution with an N-cyclopropyl substituent, introduced
by the procedure of Gillaspy, lowers the basicity of a substituted amine by 1-2 log units (per
cyclopropyl substituent) as she has shown.49 Varying the substituents at the distal phenyl 3- and
4-positions affected potency and selectivity more profoundly, and also affected pk in the αTHPs, and limited the selection of aryl substituents selected for installation in the α-piperidines,
ultimately pointing to trifluoromethyl-containing derivatives in the 4-position of the distal phenyl
ring as having optimal properties overall. Substitution with a 4-methoxy group on the distal
phenyl ring (R2 =4-MeOPh) combined with an N-propargyl substituent on the piperidine gave
19a which exhibited good potency and selectivity and a very high Cmax, but a modest half life of
1.0 h. Hydroxamate 19b with a bulky N-2-pyridylmethyl substituent on the α-piperidine
exhibited comparable potencies at MMPs-1, -2 and -13, but lost two orders of magnitude potency
versus MMP-3, while gaining an order of magnitude potency at MMPs-8 and 9. Meanwhile, the
exposure in the rat was roughly a third of the exposure of the corresponding α-piperidine Npropargyl analog. Hydroxamate 19c with an N-cyclopropylpiperidine and bearing a 4-ethoxy

group in P1´ had comparable potencies at target MMPs while losing some selectivity toward
MMP-1. Para-isopropylphenyl ether 19d exhibited good potencies and selectivity, though losing
some potency for MMP-9. In the rat, a fairly high initial Cmax of 5300 ng/mL was due in part to
the higher clogP of 3.08, yet the compound was rapidly cleared by 6 h, with a t1/2 of less than one
hour, presumably due to metabolism of the isopropyl group. Some hemolysis was apparent with
this compound as judged by blood observed in the urine. Isopropylphenyl compound 19e had
good potency for MMPs-2 and -13 and selectivity versus MMP-1, while isopropylphenyl Nisopropylpiperidine 19f was surprisingly somewhat less potent at target isozymes, although
solubility may have been an issue, giving the higher clogP fo 3.49. These 4-isopropylphenyl
derivatives were not advanced due to concern about the hemolysis observed in the iv arm with
19d. Extension of the 4-substituent as isopropyl ethers 19g and 19h showed potency for target
isozymes, but these derivatives were also unexpectedly more potent versus MMP-1, in particular
19h with a potency of 770 versus MMP-1. 4-Methylsulfone 19i backed off on potency versus
MMP-13 by almost 30X relative to some analogs. Interestingly, whereas most analogs did not
spare the non-target MT1-MMP (MMP-14) enzyme, 19i was 1200X selective for MMP-13 over
MT1-MMP. This elicited some excitement later on, when our focus shifted to dual MMP-1/14
sparing compounds, but was not initially considered as a criterion for advancement. The
sesamol-derived 1,3-benzodioxole derivative 19j with a free piperidine NH was slightly less
potent than N-alkyl piperidines, and its oral exposure in the rat was modest, as we had seen for
N-unsubstituted piperidines in the first-generation series. The poor pk of the unsubstituted
piperidines may be due to the lower logP (clogP = 0.74 for 19j) or the first-pass metabolism of
the free piperidine NH, or both. Sesamol-substituted N-poropargyl piperidine 19k exhibited a
very high exposure when dosed orally as judged by the high Cmax of over 18,000 ng/mL, but the

half life was less than 1 h. N-Methoxyethyl piperidine 19l was virtually identical to propargyl
derivative 19k based on the enzyme profile. Installation of an N-cyclopropyl substituent on the
piperidine gave hydroxamate 19m which was potent and selective, with moderate exposure in
the rat. The ring-expanded 1,4-benzodioxane 19n displayed good potency and selectivity, but
had a moderate bioavailability of 16.6%. The 4-trifluoromethylphenyl ether 19o bearing an Ncyclopropyl piperidine was a very promising compound with sub-nanomolar potency for MMPs2 and 13, excellent selectivity versus MMP-1, and attenuated potency for MT1-MMP. Oral
exposure in the rat was good, with a bioavailability of 36% and a half life of nearly 1.5 h,
although slight hemolysis was detected after iv administration of the compound. Free piperidine
19p again suffered a loss of potency and reduced oral exposure as for piperidine 19j above, and
the N-morpholinyl-ethyl piperidine 19q had minimal exposure in the rat and only 2.6%
bioavailability, demonstrating that the additional basic site in this analog was counterproductive.
N-Isopropyl piperidine 19r exhibited excellent pk in the rat with a half life of greater than 2 h
and a BA of almost 50%, but the enzyme potency was attenuated, particular for target enzyme
MMP-13. The enzyme profile of N-ethyl piperidine 19s was very comparable to Nmethoxyethylpiperidine 19t bearing the trifluorothiophenyl ether, but the methoxyethyl
derivative was chosen for pk due to the reduced basicity of its piperidine nitrogen, which we
believe to be advantageous for oral exposure. The profile of trifluoromethylthioether 19t was
deemed worthy of promotion, with one of the highest concentrations at 6 h observed overall
(14078 ng/mL), a half life of approximately 3 h and a good bioavailability of 34%, yet higher
cost of goods concerns and perhaps a bias against the somewhat less common
trifluoromethylthio functionality limited its advancement; a trifluoromethoxy group is present in
the approved drug riluzole, but there are no trifluormethylthiophenyl ethers approved or in

testing.50 In contrast, the 4-trifluoromethoxyphenyl ether contributed to overall spectacular
profiles within the series and was installed in a number of analogs, including all subsequent
analogs in Table 2, with varying piperidine N-substituents. Nonetheless, unsubstituted
piperidine 19p bearing the 4-trifluoromethyl group in P1’ suffered from limited exposure and
low bioavailability of only 6.7%, nearly identical to the rat pk of trifluoromethoxyphenyl ether
19u. On the other hand, N-methoxyethylpiperidine 19v bearing the 4-trifluoromethoxyphenyl
ether distinguished itself with exceptional inhibitory potency and 106-fold selectivity versus
MMP-1, combined with unmatched exposure after oral dosing in the rat with a BA of 68%, a
half-life of almost 3 h, and a concentration of >20000 ng/mL six hours after dosing. Thus, Nmethoxyethylpiperidine hydroxamate 19v was selected for development as a 50 pM inhibitor of
the gelatinases (MMP-2 and MMP-9) with 100,000-fold selectivity over MMP-1. The other topperforming piperidine N-substituent, the cyclopropyl, was also incorporated giving rise to Ncyclopropylpiperidine 19w, with an enzyme profile nearly identical to 19v, and with a very good
pk profile in the rat including a similar t1/2 to 19v of just under 3 h and lower but acceptable BA
of 23%. This compound was selected as the development back-up to 19v. N-2-Pyridylmethyl
and N-3-pyridylmethylpiperidine analogs 19x and 19y were very attractive compounds from the
perspective of potency and selectivity, and also in consideration of their high exposures and
bioavailabilities of ca. 47% and 50%, respectively, although their half lives in the rat were just
over one hour. The shorter half-lives were a concern for these two pyridylmethyl derivatives, as
well as higher the protein binding, as indicated by 110-fold and 123-fold shifts in MMP-2
inhibitory potency, respectively, in the presence of human plasma in a classic plasma-shift
assay,51 compared with the somewhat-lower 69-fold and 38-fold for 19v and 19w, respectively.
N-Ethoxyethyl- and N-hydroxyethyl- piperidines 19z and 19aa were potent and selective, with

food exposure in the rat, but with only a 14.7 % bioavailability (19z) and a 1.39 h half life
(19aa), respectively. Acetamide derivative 19bb maintained excellent potency and selectivity,
but the pk in the rat dropped precipitously to only 4% BA and very low plasma concentrations.
N-Propargyl piperidine hydroxamate 18cc was potent and selective, and bears the same
piperidine substituent as first-generation MMP-1 sparing hydroxamate 6. We shied away from
propargyl substituent as it did not afford any advantages over N-methoxyethyl or N-cyclopropyl
(among other substituents), and we observed that it forms 1-2% of a vinyl chloride impurity in
the final API (active pharmaceutical ingredient) upon HCl deprotection of the THP-protected
hydroxamate. N-Methyl and N-isopropyl piperidine derivatives 19dd and 19ee were potent and
selective, and should have favorable pk profiles in the rat, but were simply not advanced.
Thus, preparation of the α-THP derivatives enabled rapid exploration of SAR, but these
compounds had poorer pk profiles than the corresponding α-piperidines. The trifluoromethylsubstituted analogs 9i, 9j and 9l are notable exceptions with excellent pk profiles, and these P1´
substituents performed well in the α-piperidine series as well. We believe that this enhancement
is the result of blocking metabolism at the para position of the terminal phenyl ring of the diaryl
ether as well as enhanced membrane penetration due to fluorine substitution.52

N-

Methoxyethylpiperidine 19v and N-cyclopropylpiperidine 19w, both bearing the distal
trifluoromethoxyphenyl group in P1´, were promoted for full efficacy evaluation, and α-THP 9i
was also considered a top priority compound to augment the structural diversity the leads and
spread the risk among different chemistries.

Crystallography

The crystal structure of MMP-13 in complex with 19v was determined at 1.9Å resolution
(Rfree=25.6%; PDB accession code: 3KRY) and shows the compound forming an intricate web of
contacts to the catalytic zinc ion and surrounding amino acids (Figure 2). Two hydrogen bonds
are made between an oxygen atom of the sulfone moiety and the protein backbone, and an
additional hydrogen bond is made from the nitrogen of the hydroxamate function to the protein
backbone (Figure 2A). The two oxygen atoms of the hydroxamate coordinate to the metal, and
an additional interaction is formed with the sidechain of Glu223. For that close interaction
(2.8Å), it is assumed that either the Glu residue or the hydroxamate oxygen is protonated. The
diphenyl ether tail of the compound protrudes deeply into the S1’ subsite, which is in an open
conformation. Five ordered solvent molecules bridge across the two sides of the pocket and
encapsulate the trifluormethyl tail of the compound.

Figure 2. Structure of 19v and origins of its selectivity. A) Complex of 19v bound at the MMP13 active site. Hydrogen bonds and metal (green sphere) coordination is depicted as dotted lines.
Solvent molecules are shown as red spheres. B) Superposition of the catalytic domains of MMP1 (PDB accession code: 1HFC) and the 19v:MMP-13 complex. The molecular surface for
Arg214 of MMP-1 is drawn to demonstrate its steric blockade of inhibitors with sufficient length
of their S1´ substituents.

Metalloproteinase selectivity for 19v was achieved by exploiting the larger S1´ pocket found in
MMP-13 compared to other MMPs, such as MMP-1. As was previously reported,53-55 MMP-1
and MMP-13 S1´ pockets differ in two key ways. First, the length of the loop and thus the depth
of the pocket are shorter in MMP-1 because of a two residue deletion in that sequence relative to
MMP-13. In addition, MMP-1 has a significantly larger residue, Arg214, in place of Leu218 in

MMP-13. This presents a steric blockade for inhibitors of sufficient length from binding to the
S1´ site. The relevance of this amino acid difference was evaluated for 19v by superimposing
the structure of MMP-1 (PDB accession code: 1HFC) onto the structure of MMP-13 with 19v.
Overall, the two catalytic domains aligned well, differing by an RMSd of only 0.75Å over 154
residues aligned. However, at the S1´ subsite, their structures diverged as expected with MMP-1
presenting a significantly smaller cavity within which the compound would have to fit. In the
case of 19v, the diphenyl ether tail of the compound would collide with the Arg sidechain in
MMP-1 (Figure 2B). While this Arg residue has been observed in alternate conformations in
MMP-1 with compounds similar to 19v55 the molecular determinants for when that conformation
is accessible and its relevance to full length enzyme remain unclear.
As noted above, the piperidine N-substituents (R1) extend into solvent and generally had
little or no impact on potency at MMP-13, although the larger 2-pyridylmethyl substituent of 19b
did impact selectivity toward several other isozymes.

The capacity for the P1´ pocket to

accomodate such large moieties as the biphenyloxyphenylsulfone of 9g is rather remarkable, but
also demonstrates that the pocket is both flexible and open at the bottom, near Phe252. The size
of the pocket is consistent with the inability to substitute only on the 3- and/or 4-positions of the
distal phenyl ring in P1´. The substituents at the terminus of the distal phenyl ring in P1´ are
surrounded by the hydroxyl of Thr 245, the methyl of Thr247, the edge of the phenyl ring of
Phe252, and the hydrophobic chain of Leu218, plus several solvent (water) molecules. Smaller,
hydrophobic but polarizable moieties tended to be the best aryl substituents at this position. The
distance of 2.87 Å between F35 and the Thr245 oxygen is more consistent with a simple Van der
Waals interaction than a potential but very rare56 OH…F hydrogen bond.

Antitumor Efficacy
Marimastat and AG-3340 are effective in preclinical models of cancer but produce a doselimiting musculoskeletal syndrome characterized as joint fibrosis, pain and limited mobility in
humans. As noted above, one strategy for improving the therapeutic index of MMP inhibitors is
to design selective inhibitors of the MMPs that promote neoplastic growth while sparing MMP1, a widely distributed collagenase thought to play a central role in connective tissue
homeostasis. Hydroxamate 19w is a potent inhibitor of several MMPs with IC50’s of 0.2nM,
56.5nM, 1.0nM, <0.1nM and 0.2nM against MMP-2, -3, -8, -9, and -13 respectively. Although
potent against MMPs that are thought to play a significant role in angiogenesis and tumor
growth, 19w is highly sparing of MMP-1 (IC50 = 3883 nM). The IC50 of 19w for MMP-1 is 100fold greater than that of AG-3340.57 Hydroxamate 19w has good oral bioavailability and halflife across multiple species, and it is well tolerated in mice dosed twice daily for greater than 90
days. MMPi 19w is a dose-dependent and potent inhibitor of angiogenesis in the mouse bFGFinduced corneal micropocket model and delays tumor growth in variety of models of human
cancer including the androgen-independent PC3 human prostate tumor, the difficult-to-treat
SKMES human lung carcinoma (data not shown) and MX-1 human breast tumors was
significantly inhibited by treatment of tumor-bearing mice with 19w.

The efficacy of 19w in the PC3 tumor growth delay model, either as single agent or in
combination with cisplatin, is shown in Figures 3a and 3b. BALB/c nu/nu mice, implanted with
PC3 cells were administered 19w twice daily beginning on the day of cell injection. Tumor
volume was measured over the course of the experiment. MMP inhibitor 19w inhibited PC3

tumors in a dose responsive manner; animals dosed with 100 and 200 mg/kg 19w inhibited
tumor growth by greater than 65% (p<0.001 vs vehicle -treated mice).

MMPi 19w in combination with cisplatin therapy was more effective than treatment with either
agent alone. Mice implanted with PC3 cells and administered 19w by gavage twice daily were
injected with a single intraperitoneal injection of cisplatin on day 8. Treatment of mice bearing
PC3 tumors with 10 mg/kg 19w or 10mg/kg cisplatin inhibited tumor growth by 49% and 53%,
respectively, whereas PC3 tumor growth was inhibited by 78% in mice treated with 19w and
cisplatin.
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Figures 3a and 3b. Efficacy of 19w in the PC3 tumor growth delay model, either as single
agent or in combination with cisplatin

35

MMPi 19w was shown to significantly delay the growth of MX-1 human breast tumors in nude
mice when used as a single agent (data not shown). Inhibitor 19w was subsequently tested in
the MX-1 adjuvant model; a clinically relevant disease model designed to determine the
anticancer activity of non-traditional, non-cytotoxic agents in a setting of minimal tumor burden.
Mice bearing MX-1 tumors were treated with cyclophosphamide (CY) and beginning
approximately two weeks later mice were administered 19w delivered by gavage, twice a day
over the remainder of the experiment. Efficacy was measured by survival extension. As shown
in Figure 4, adjuvant therapy with 19w, following initial cytoreduction of MX-1 breast
carcinomas in nude mice by CY treatment greatly increased the survival times of animals
compared to treatment with CY monotherapy. CY alone (120 mg/kg) extended survival by
three weeks compared to saline controls. High dose 19w (50 mg/kg) following CY treatment
further increased the mean survival time of mice by an additional four weeks compared to CY
monotherapy. Significant survival gains over CY monotherapy were shown for all doses of 19w
following CY treatment. The highly effective adjuvant therapy seen with 19w after CY
treatment was obtained with no side effects, indicating that the adjuvant efficacy was achieved
with a good therapeutic index.
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Figure 4. Survival extention provided by 19w to mice bearing MX-1 tumors

These results support the potential utility of 19w in the treatment of patients with malignancies
of the lung, prostate and breast.

Inhibition of Cartilage Degradation

Osteoarthritis (OA) is a degenerative disease of the joints that is characterized by the progressive
degeneration and loss of articular cartilage. Current treatments focus on alleviating the pain
associated with OA but do not address the underlying disease process. While the precise
etiology of OA is not known, it appears to be the result of a complex system of interacting
mechanical, biologic, biochemical, and enzymatic feedback loops. The final common pathway
of articular cartilage deterioration results from a failure of chondrocytes to maintain a
homeostatic balance between matrix synthesis and degradation. The major matrix components
of articular cartilage, aggrecan and collagen, provide the physical properties essential for

maintaining joint function, compressibility and tensile strength, respectively. Accumulating
evidence implicates an imbalance between intraarticular synthesis of matrix-degrading enzymes,
particularly MMPs, and their endogenous tissue inhibitors of metalloproteinases (TIMPs) as
causally associated with cartilage loss in OA.

In that no disease-modifying OA drugs (DMOADs) have yet been approved, animal models
capable of predicting efficacy in human disease have not been validated. Furthermore, the
translatability of relatively acute in vivo preclinical models to the human disease which develops
over decades is not known. However, in an attempt to provide early evidence of the cartilage
protective properties of test compounds, a cytokine-induced bovine nasal cartilage degradation
(BNCD) assay was developed and has been used to evaluate the importance to cartilage
metabolism of numerous targets. Using an adaptation of the assay described by Bottomley, et
al,58 selected compounds were tested for their ability to inhibit cartilage degradation.
Importantly, this model system allows for the concentration-dependent characterization of
compounds, including endpoint measurements that reflect both loss of aggrecan and collagen.
Additionally, the same collagenase-dependent collagen fragments generated using this in vitro
system have also been detected in urine, providing some confidence that this assay may be
relevant to what occurs in the whole animal.

The α-THP sulfone 9i, which had an IC50 of 0.4 nM when assayed using a purified MMP-13
enzyme preparation and synthetic small molecule as substrate, exhibited an IC50 of 70 nM in the
BNCD assay (Figure 5). The α-piperidine 19w was somewhat more potent than α-THP 9i in
both the enzyme (IC50 = 0.1 nM) and cartilage explant (IC50 = 10 nM) assays. Compound 5,

which was included as a standard in all BNCD assays, had an IC50 = 0.6 nM and 30 nM in the
enzyme and explant assays, respectively. A complete understanding of the reduced potency
demonstrated by these compounds in the explant system relative to the purified enzyme system is
not known. However, this right-shift in potency was a consistent feature of all compounds tested
and may represent differences between synthetic and native substrates, ability of inhibitors to
reach the target enzyme in the cartilage matrix, or microenvironments in the cartilage that are not
represented in the purified system assay.

Further demonstration of the cartilage-protective potential of these compounds was evidenced by
a reduction of collagenase-dependent type II collagen fragments excreted in the urine of healthy
dogs treated with the alpha-piperidine sulfone MMP inhibitor 19v (data not shown). Consistent
with the pharmacokinetic properties of this compound in canine, urinary collagen fragment
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Figure 5. MMP inhibitors protect bovine nasal cartilage from cytokine-induced degradation in
the ex vivo cartilage explant assay of Billinghurst.59 Individual uniform cartilage disks were
treated with cytokines (IL-1 and oncostatin M) in the presence of 19w (squares) or 9i
(diamonds). HO-Pro released into the supernatant over 16 days of tissue culture was measured
to determine cartilage breakdown, 0% and 100% degradation were defined as the HO-Pro
released from inhibitor-free cartilage without and with cytokine stimulation,
respectively. Quantification of HO-Pro release as a function of inhibitor concentration (1 nM to
1 uM) allowed for IC50 determinations estimated at 10 nM and 75 nM for 19w and 9i,
respectively. Each data point represents the average of at least three independent incubations
and error bars indicate the standard deviation of the data for the specific condition.

Inhibition of post-infarction left ventricular dilation

The effects of α-piperidine 19w and α-THP 9i on left ventricular (LV) dilation following
myocardial infarction were investigated in a rat model of myocardial infarction (MI). MI was
induced by permanent ligation of the left coronary artery as previously described.60 The efficacy
of 19w and 9i in reducing post-infarction LV dilation was assessed by ex vivo diastolic pressurevolume relationship a measure of LV size and compliance, as described by Fletcher et al.61
MMP inhibitors 19w and 9i were administered orally at doses of 10 and 50 mg/kg/day (qd) for
four weeks. LV dilation was significantly shifted to the right in the MI-vehicle group relative to
the sham-vehicle group, indicating significant LV dilation. At an intraventricular pressure of 40
mmHg, the mean LV volume of the MI-vehicle group (0.69 ± 0.02 mL) was significantly greater
than the sham-vehicle group (0.55 ± 0.02 mL). Both 19w and 9i produced dose-dependent

inhibition of post-infarction LV dilation (Figure 6). 50 mg/kg 19w and 9i significantly
attenuated LV dilation, with mean LV volumes of 0.62 ± 0.01 mL and 0.63 ± 0.03 mL,
respectively (p<0.05 vs. MI-vehicle group, 0.69 ± 0.02 mL).
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Figure 6. Effect of 19w and 9i on LV post-MI. * p<0.05 vs. Sham-vehicle, #p<0.05 vs. MIvehicle

In a separate experiment, the efficacy of 19v in reducing post-infarction LV dilation was
assessed. Compound 19v was administered orally at doses of 0.01, 0.1, 1, and 10 mg/kg/day
(qd) for four weeks following MI. The LV diastolic pressure-volume relationship of the MIvehicle group was significantly shifted to the right compared to the sham-vehicle group (Figure
7). At an intraventricular pressure of 40 mmHg, the mean LV volume of the MI-vehicle group
(0.59 ± 0.02 mL) was significantly greater then that of sham-vehicle group (0.49 ± 0.02 mL).
Hydroxamate 19v produced a dose-dependent inhibition of post-infarction LV dilation. At dose
of 10 mg/kg, 19v significantly attenuated LV dilation, with mean LV volume of 0.51 ± 0.02 mL
(p<0.05 vs. MI-vehicle group, 0.59 ± 0.02 mL).
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Conclusions

Our first-generation MMP-1 sparing hydroxamate development candidate 6 was replaced by Nmethoxyethyl α-piperidine sulfone 19v, with N-cyclopropylpiperidine hydroxamate 19w as the
backup compound. Compound 6 was ultimately deemed inferior to the compounds described in
this manuscript due to its metabolically-labile piperidine N-propargyl group and diaryl thioether,
and the presence of vinyl chloride in the final product after final HCl deprotection of the THPprotected hydroxamate. Furthermore, the present diaryl ether compounds were generally
superior in potency, selectivity and pharmaceutical properties.

Compound 19v is a ca. 100 pM inhibitor of MMP-13 and the gelatinases (MMP-2 and MMP-9)
with >100,000-fold selectivity over MMP-1 for MMP-2 and MMP-13, and >50,000-fold
selectivity for MMP-9 over MMP-1. We have found that 19v does not inhibit TNFα release in a
cellular assay. The compound has good oral bioavailability (52 to 82%) in the mouse, rat, dog,
and cynomolgus monkey (Table 3), including the species used for testing cancer efficacy (tumor
bearing mice) and cardiovascular post-MI efficacy (rat). It is rapidly absorbed after oral dosing,
with a Tmax ranging from 10 min (mouse) to 4 hours (rat). The elimination half life (T1/2) ranges
from 4 to 6 hr. Compound 19v shows dose-dependent inhibition of angiogenesis in the mouse
corneal micropocket model with a maximal inhibition of about 60% at 5 mg/kg, b.i.d. It also
demonstrates dose-dependent inhibition of tumor growth of human prostate PC3 with efficacy
that is additive with cisplatin and nearly achieving stasis at the highest dose tested.

Nonetheless, although 19v caused less joint fibroplasia in rats, the marmoset indicated that MSS
would still be an issue clinically, and we realized that an MMP-1 sparing approach was not
adequate to provide joint safety. While this side effect is obviously unacceptable for OA, the
merits of a short-term regiment post-MI in the prevention of CHF are arguable. But even for
life-threatening cancer, dose limitations and holidays due to MSS have limited the efficacy and
effectiveness of MMP inhibitors in the clinic. Specifically, these highly MMP-1-sparing
inhibitors were not completely devoid of fibroplasia in either rat or marmoset, consistent with the
findings of others.21 Thus, toward attaining the greatest promise of safety, we turned our
attention to even more selective profiles, specifically to a dual-sparing approach, sparing both
MMP-1 and MMP-14 (MT-1 MMP), based on the observation that MT-1 MMP knockout mice
suffer connective tissue disease due to inadequate collagen turnover62 and impaired
endochondral ossification63 histologically similar to joint lesions in MSS. We subsequently
found that highly selective compounds that spared both MMP-1 and MMP-14 do maintain
efficacy in attenuating cardiovascular post-MI hypertrophy as well as maintaining antitumor
efficacy, without eliciting a similar joint toxicity, despite the reported potential role for MMP-14
itself in tumor growth, invasion, and neovascularization.64 Our initial progress toward dual
MMP-1/14 sparing inhibitors, including modifications in the P’ region incorporating aryl
piperidines and isonipecotamide derivatives that are highly selective for MMP-13 and sparing of
both MMP-1 and MMP-14 has just been reported,44, 45 and the discovery of joint-safe, dual
MMP-1/14-sparing hydroxamate MMPi’s with oral antitumor efficacy in mice and the ability to
block post-MI LV hypertrophy in rats will be reported in due course.

Experimental Section

General Procedures and Analysis. All solvents and reagents were used without further
purification unless otherwise noted. All reactions were performed under an atmosphere of
nitrogen or argon. Merck silica gel 60 (230-400 mesh) was used for flash chromatography.
Merck Kieselgel 60 F254 DC-Fertigplatten (0.25 mm, Art. 5719) were used for TLC. High
performance liquid chromatograms (HPLC) were obtained from YMC AQ C-18 reverse phase
columns. 1H NMR spectra were obtained from either General Electric QE-300 or Bruker-400
MHz Ultrashield spectrometers with tetramethylsilane (TMS) as an internal standard. Noisedecoupled and APT 13C NMR spectra were recorded at 75 MHz on a General Electric QE-300
spectrometer. IR spectra were recorded on a Perkin Elmer 685 spectrophotometer. DSC refers
to differential scanning calorimetry. MIR refers to multiple internal reflectance infrared
spectroscopy. DMAC refers to N,N-dimethylacetamide. EDC refers to 1,3(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride. NMM refers to Nmethylmorpholine. High-resolution mass spectra were recorded on a Finnigan MAT8430
instrument. Elemental analyses were conducted on a Control Equipment CEC240-XA
instrument. All final products were analyzed for purity by reverse-phase hplc eluting with a
gradient of acetonitrile/water and were determined to be ≥95% pure. All animal work was
carried out in accordance with institutional guidelines. All animal procedures were approved the
Institutional Animal Care and Use Committee and conform to the NIH Guidelines for the Ethical
Care and Treatment of Animals.

Tetrahydro-N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-2H-pyran- 4-carboxamide (9a). To
a stirred solution of α-tetrahydropyranyl 4-fluorophenylsulfone methyl ester 7, (0.96 g, 3.2 mmol)
in DMF(30 mL) was added phenol (0.3 g, 3.2 mmol), followed by Cs2CO3 (3.2 g, 10 mmol). The
resulting mixture was heated to 70°C for 5 hours. The solution remained at ambient temperature
for 18 hours, was diluted with H2O and extracted with EtOAc. The organic layer was washed
with half-brine and dried over Na2SO4. The solvent was removed by rotary evaporation to yield
the desired diaryl ether methyl ester (1.1 g, 92%). Sodium hydroxide (1.0 g, 25 mmol) was
added to a solution of the methyl ester (1.1 g, 2.9 mmol) in THF (10 mL) and ethanol (10 mL).
The resulting solution was stirred at ambient temperature for 1 hour. The solution was then
heated to 80°C for 1 hour. The solvent was removed by rotary evaporation and the resulting
sodium salt was acidified with 1 N HCl (50 mL) and extracted with EtOAc. The organic layer
was dried over Na2SO4 . The solvent was removed by rotary evaporation to yield the desired
carboxylic acid 8a (1.1 g, 99%).
To a stirred solution of carboxylic acid 8a (1.1 g, 3.0 mmol) in DMF (7 mL) was added Nhydroxybenzotriazole-H2O (0.623 g, 4.6 mmol), followed by 1-[3-(dimethylamino)propyl]-3ethylcarbodiimide hydrochloride (0.634 g, 3.3 mmol). After 10 minutes, a 50% aqueous
hydroxylamine solution was added (2 mL, 30 mmol) and the solution was stirred at ambient
temperature for 18 hours. The solution was diluted with saturated NaHCO3 and extracted with
EtOAc. The organic layer was washed with water and followed by half-brine and then dried over
Na2SO4. Reverse phase chromatography (on silica, acetonitrile/H2O) provided the hydroxamate
9a as a white solid (0.37 g, 33%). HRMS (ES+) MH+ for C18H19NO6S, 378.1011, found:
378.0994.

4-[[4-(3-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- 2H-pyran-4-carboxamide
(9b). Fluorophenylsulfone THP-protected hydroxamate 10 was prepared from methyl ester 7 by
hydrolysis with trimethylsilanoate followed by coupling with O-(tetrahydro-2H-pyran-2yl)hydroxylamine and EDC as previously described.42 To a solution of fluorophenylsulfone 10
(5.0 g, 13 mmol) in DMF (20 mL) was added p-chloro-phenol (5.0 g, 39 mmol), followed by
Cs2CO3 (17 g, 52 mmol). The resulting solution was heated to 95°C for 7 hours. The solution
was maintained at ambient temperature for 7 hours, diluted with water and extracted with EtOAc.
The organic layer was washed with half-brine and dried over Na2SO4. The solution was
concentrated by rotary evaporation. Chromatography (on silica, EtOAc/hexane) provided the mchloro phenoxyphenyl THP-protected hydroxamate compound 11b (5.2 g, 82%).
To a solution of the m-chloro phenoxyphenyl THP-protected hydroxamate 11b (5.2 g, 10 mmol)
in dioxane (5 mL) was added 4N HCl in dioxane (5 mL, 20 mmol), followed by methanol (10
mL). The resulting solution was stirred at ambient temperature for 1 hour. The solvent was
removed by rotary evaporation to provide the hydroxamate 9b as a white solid (3.4 g, 79%). . 1H
NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1 H), 9.18 (d, J=1.56 Hz, 1 H), 7.73 (d, J=8.99 Hz, 2 H),
7.51 (t, J=8.20 Hz, 1 H), 7.36 (d, J=8.99 Hz, 1 H), 7.32 (t, J=2.15 Hz, 1 H), 7.18 (d, J=8.99 Hz, 2
H), 7.15 (dd, J=7.81, 1.95 Hz, 1 H), 3.88 (dd, J=11.53, 3.71 Hz, 2 H), 3.16 (t, J=11.33 Hz, 2 H),
2.22 (d, J=12.50 Hz, 2 H), 1.83 - 1.98 (m, 2 H). HRMS (ES+) M.NH4+ calcd for C18H18NO6SCl
429.0887; found: 429.0880. HRMS MH+ calcd for C18H18NO6SCl, 412.0622; found, 412.0615.

4-{[4-(4-Chlorophenoxy)phenyl]sulfonyl}-N-hydroxytetrahydro-2H-pyran-4-carboxamide
(9c). The α-THP p-chlorophenyloxyphenylsulfone 9c was prepared as previously described.42

4-[[4-(3,4-dichlorophenoxy)-phenyl]sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4carboxamide (9d). To a solution of fluorophenylsulfone 10 (3.1 g, 8 mmol) in N,N-DMAC (20
mL) were added Cs2CO3 (8.8 g, 27 mmol) and 3,4-dichlorophenol (2.61 g, 16 mmol). The slurry
was stirred at 95°C for 41 hours. The reaction was concentrated in vacuo, and the residue was
taken up in EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.
Chromatography (on silica, EtOAc/hexanes) provided the substituted THP-protected
hydroxamate 11d as a white foam (4.17 g, 98%). MS (ES+) M.NH4+ calcd for C23H25NO7SCl2,
547.11; found 547.10.
To a slurry of the THP-protected hydroxamate 11d (3.5 g, 6.6 mmol) in dioxane (20 mL) were
added a 4N HCl dioxane solution (20 mL) and methanol (20 mL). After fifteen minutes at
ambient temperature the reaction was diluted with EtOAc and washed with water, dried over
Na2SO4, filtered, and concentrated in vacuo. The residue was slurried in diethyl ether and
vacuum filtration of the resulting precipitate provided the hydroxamate 9d as a white solid (2.98
g, 100%). MS (ES+) M.NH4+ calcd for C18H17NO6SCl2, 463.05; found, 463.05.

N-hydroxy-4-{[4-(4-hydroxyphenoxy)phenyl]sulfonyl}tetrahydro-2H-pyran-4-carboxamide
(9e). To a solution of fluorophenylsulfone 1042 (2.7 g, 7.0 mmol) in DMAC (20 mL) was added
Cs2CO3 (6.84 g, 21 mmol) and 4-(benzyloxy)phenol (2.8 g, 14 mmol). The slurry was stirred at
95°C for 6 h. The reaction was concentrated in vacuo and the residue was taken up in EtOAc,
washed with brine, dried over Na2SO4, filtered and concentrated. Chromatography on silica gel
eluting with EtOAc/hexanes provided the diaryl ether 11e as a white foam (3.94 g, 99%). MS
(ES+) M.NH4+ calcd for C30H33NO8S, 585.23; found, 585.23.

To a solution of the THP-protected hydroxamate 11e (1.5 g, 2.64 mmol) in glacial acetic acid (5
mL) was added concentrated HCl (5 mL) and the reaction was heated to 60°C for 20 min. The
reaction was cooled, diluted with water (100 mL) and extracted with EtOAc. The EtOAc extract
was washed successively with water (3X) and brine, dried over Na2SO4, filtered and
concentrated in vacuo. The product was recrystallized (acetone/hexanes) to give hydroxamate 9e
as a white solid (810 mg, 78%). 1H NMR (400 MHz, DMSO-d6) δ 10.96 (1H br s), 9.54 (1H, s),
9.16 (1H, s), 7.59 - 7.82 (2H, m), 6.95 - 7.14 (4H, m), 6.77 - 6.95 (2H, m), 3.86 (2H, dd, J=11.4
Hz), 3.15 (2H, t, J=11.6 Hz), 2.20 (2H, d, J=13.1 Hz), 1.76-1.96 (2H, m). MS (ES+) M.MH4+
calcd for C18H19NO7S, 468.15; found, 468.15. HRMS MH+ calcd for C18H19NO7S 394.0960,
found 394.0962.

N-hydroxy-4-{[4-(4-isopropoxyphenoxy)phenyl]sulfonyl}tetrahydro-2H-pyran-4carboxamide (9f). To a solution fluorophenylsulfone 1042 (3.1 g, 8.0 mmol) in DMAC (20 mL)
was added Cs2CO3 (7.28 g, 24 mmol) and 4-isopropoxyphenol (2.4 g, 16 mmol). The slurry was
stirred at 95°C for 21 h. The reaction was concentrated in vacuo. The residue was taken up in
EtOAc, washed successively with water (3X) and brine, dried over Na2SO4, filtered and
concentrated in vacuo. Chromatography on silica gel eluting with EtOAc/hexanes provided the
diaryl ether 11f as an off-white foam (3.65 g, 88%). MS (IS+) MH+ calcd for C26H33NO8S,
520.20; found, 520.20.

To a solution of the THP-protected hydroxamate 11f (3.5 g, 6.7 mmol) in 1,4-dioxane (17 mL)
was added 4N HCl in dioxane (17 mL) and methanol (17 mL). After 15 min at rt the reaction
was diluted with EtOAc and washed with water, dried over Na2SO4, filtered, and concentrated in

vacuo. The product was recrystallized (acetone/hexanes) to give the hydroxamate 9f as an offwhite solid (2.2 g, 80%). 1H NMR (400 MHz, DMSO-d6) δ 10.97 (1H, s), 9.16 (1H, s), 7.58 7.78 (2H, m), 6.93-7.23 (6H, m), 4.60 (1H, dt, J=11.9 Hz), 3.86 (2H, dd, J=11.5 Hz), 3.15 (2H, t,
J=11.6 Hz), 2.21 (2H, d, J=12.9 Hz), 1.87 (2H, td, J=4.5 Hz), 1.25-1.40 (2H, m). MS (ES+)
MH+ calcd for C21H25NO7S, 436.14; found, 436.14. HRMS calcd for C21H25NO7S 436.1430,
found 436.1431.

4-[[4-([1,1′-biphenyl]-4-yloxy]phenyl)sulfonyl]tetrahydro- N-hydroxy-2H-pyran-4carboxamide (9g). To a solution fluorophenylsulfone 9 (2.0 g, 5.2 mmol) in DMAC (8 mL) was
added 4-phenylphenol (Aldrich, 1.3 g, 7.8 mmol) followed by Cs2CO3 (6.8 g, 20.8 mmol). The
reaction was heated at 95°C for five hours. Stripping the DMAC in vacuo afforded a brown solid
(5.3 g, 100%). Preparative reverse-phase chromatography on a C-18 column eluting with
acetonitrile/water gave the THP-protected biphenyl product 11g in solution. To this solution of
11g in acetonitrile/water (50 mL) was slowly added 10% HCl aq (100 mL). After stirring
overnight for 18 hours) the acetonitrile was removed in vacuo. The resultant precipitate was
collected, giving the hydroxamate 9g as a white solid (2.0 g, 83%). 1H NMR (300 MHz, DMSOd6) δ 1.75 - 1.99 (2H, m), 2.21 (2H, d, J=12.9 Hz), 3.15 (2H, t, J=11.3 Hz), 7.11-7.31 (2H, m)
3.85 (2H, d), 7.31-7.52 (2H, m), 7.61-7.82 (6H, m), 10.97 (1H, br s). MS (FAB) MH+ calcd for
C24H23NO6, 454; found, 454.

N-hydroxy-4-({4-[3-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4carboxamide (9h). To a solution of fluorophenylsulfone 1042 in DMAc (20 mL) was added
CsCO2 (7.28 g, 24 mmol) and m-(trifluoromethyl)phenol (1.95 mL, 16 mmol). The slurry was

stirred at 95°C for 20 h. After the reaction mixture was concentrated, the residue was dissolved
in EtOAc and washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.
Chromatography on silica gel eluting with EtOAc/hexane provided the diaryl ether 10h as a
white foam (4.1 g, 97%). HRMS (ES+) MH+ calcd for C24H26NO7SF3, 530.15; found, 530.14.

To a solution of the THP-protected hydroxamate 11h (3.9 g, 7.4 mmol) in 1,4-dioxane (20 mL)
was added 4N HCl in dioxane (20 mL) and methanol (20 mL). After 15 min at rt the reaction
was diluted with EtOAc and washed with water, dried over Na2SO4, filtered, and concentrated in
vacuo. The residue was crystallized from acetone/hexanes to give the hydroxamate 9h as a white
solid (1.9 g, 58%). 1H NMR (400 MHz, DMSO-d6) δ 10.99 (1H, s), 9.18 (1H, s), 7.69-7.82 (3H,
m), 7.63-7.69 (1H, m), 7.58 (1H, s), 7.49 (1H, d, J=8.0 Hz), 7.17-7.25 (2H, m), 3.88 (2H, dd,
J=11.5 Hz), 3.16 (2H, t, J=11.6 Hz), 2.22 (2H, d, J=12.9 Hz), 1.90 (2H, td). HRMS (ES+) MH+
calcd for C19H18N3O6SF3, 446.09, found 446.09. HRMS calcd for C19H18N3O6SF3, 446.0885;
found, 446.0872.

N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4carboxamide (9i). According to the general method of Samaritoni[J Het Chem 1997 34(4)
1263-1266] in dry equipment under nitrogen, sodium hydride (60% oil dispersion, 11.0 g, 0.275
mol) was added to a solution of 4-[4-(trifluoromethyl)phenoxy]-phenol 10 (50.0 g, 0.197 mol) in
dry DMF (150 mL) at 0°C. After 15 min, a solution of dimethylthiocarbamoyl chloride (32.0 g,
0.259 mol) in dry DMF (100 mL) was added. The reaction was stirred at rt for 16 h. The
reaction was poured onto 10% aqueous HCl (1 L). Vacuum filtration of the resulting precipitate
provided the thiono compound as a white solid (67.0 g, 100%). The thiono derivative (67 g, 0.20

mol) was heated to 317°C for 30 min behind a safety shield. The reaction temperature rose to
330°C. The heat was removed and the reaction was allowed to cool to rt to yield the
thiocarbamate as a brown solid (67 g, 100%). To a solution of the thiocarbamate (65.0 g, 0.19
mol) in methanol (510 mL) with a subsurface nitrogen stream was added 2.5N NaOH solution
(160 mL, 0.40 mol). The slurry was stirred at 74°C for 2 h. The reaction was cooled and the
methanol removed in vacuo to yield the crude 4-[4-(trifluoromethoxy)phenoxy]-benzenethiol 13.

The crude sample of thiol 13 was diluted with water (100 mL) and extracted with diethyl ether
(4X). A subsurface stream of nitrogen was added to the aqueous solution and sodium
chloroacetate (22.2 g, 0.19 mol) was added. The reaction was stirred at rt and after 30 min the
nitrogen stream was removed. After 12 h, the solution was cooled and 6N HCl was added until
pH = 1. The slurry was extracted with EtOAc (4X), and the combined extracts were washed
with 0.1N HCl, water, and brine, and dried over Na2SO4 and filtered. Concentration in vacuo
gave the arylthioacetic acid as a tan solid (61.0 g, 98%). To a solution of the thioacetic acid
(54.45 g, 0.166 mol) in THF (370 mL) was added water (45 mL) and Oxone® (306 g, 0.498
mol) at rt. An exotherm to 42°C was noted. After 2 h, the reaction was filtered and the filter
cake was washed well with THF and then water (250 mL) was added to the filtrate. The filtrate
was concentrated in vacuo. The slurry was extracted with EtOAc (4X). The combined extracts
were washed with water three times, brine, dried over MgSO4, filtered and concentrated in
vacuo to give the sulfone 14 as a beige solid (60.0 g, 100%).

A solution of the sulfone 14 (119.5 g, 0.332 mol) in methanol (660 mL) and 4N HCl in dioxane
(20 mL) was stirred at rt for 12 h. The reaction was heated to reflux and then cooled to rt. The

resulting crystals were filtered, washed well with cold methanol, and then dried to give the
methyl ester as a white solid (89.4 g, 72%).

To a solution of the methyl ester (64.5 g, 0.180 mol) in DMF (360 mL) was added K2CO3 (66.8
g, 0.48 mol), bis(2-bromoethyl)ether (40 mL, 0.305 mol), 4-dimethylaminopyridine (1.1g, 9
mmol) and tetrabutylammonium bromide (2.9 g, 9 mmol). The reaction was stirred overnight at
rt. The reaction was slowly poured into 1N HCl (500 mL). The resulting precipitate was
filtered, washed with water and then with hexanes. The solid was recrystallized from methanol
to give the pyran methyl ester as a white solid (62.8 g, 79%). MS (ES+) M.MH4+ calcd for
C20H19O6SF3, 462.12; found, 462.12.

In dry equipment under an atmosphere of nitrogen, the pyran (64.0 g, 0.144 mol) was dissolved
in dry THF (250 mL) and a solution of potassium trimethylsilanoate (55.9 g, 0.432 mol) in dry
THF (40 mL) was added at rt. After 2 h, water (200 mL) was added and the solution was
concentrated in vacuo. The slurry was extracted with EtOAc to removed unreacted starting
material. The aqueous solution was treated with 6N HCl until pH=1. The slurry was extracted
with EtOAc and the combined extracts were washed with water and brine and dried over
Na2SO4, filtered and concentrated in vacuo. The residue was heated in diethyl ether, and the
resulting solid filtered and dried to give the carboxylic acid 8i as a white solid (56.3 g, 91%).
HRMS (ES+) M.NH4+ calcd for C19H17O6SF3 448.10, found 448.10.

To a solution of the carboxylic acid 8i (49.0 g, 0.114 mol) in dry DMF (280 mL) was added
HOBt hydrate (18.5 g, 0.137 mol), NMM (37.5 mL, 0.342 mol), O-(tetrahydro-2H-pyran-2-

yl)hydroxylamine (41.3 g, 0.353 mol) and EDC (30.6 g, 0.160 mol). After 4h at rt the reaction
was concentrated in vacuo. The residue was taken up in EtOAc, washed with water, 5% aqueous
KHSO4, saturated NaHCO3, and brine and dried over Na2SO4, filtered and concentrated to give
the THP-protected hydroxamate 11i as a white foam (62.6 g, 100%). MS (ES+) M.NH4+ calcd
for C24H26NO7SF3, 547.17; found, 547.17.

To a solution of the THP-protected hydroxamate 11i (58.5 g, 0.11 mol) in 1,4-dioxane (280 mL)
was added 4N HCl in dioxane (280 mL) and methanol (280 mL). After 15 min at rt the reaction
was diluted with EtOAc and washed with water, dried over Na2SO4, filtered and concentrated in
vacuo. The product was recrystallized (acetone/hexanes) to give compound 19p as a white solid
(42.79 g, 87%). 1H NMR (400 MHz, DMSO-d6) δ 11.00 (1H, s), 9.19 (1H, d, J=1.2 Hz), 7.687.94 (4H, m), 7.19-7.44 (4H, m), 3.88 (2H, dd, J=11.4, 3.2 Hz), 3.16 (2H, t, J=11.7 Hz), 2.23 (2
H, d, J=13.3 Hz), 1.84-2.00 (2 H, m). MS (ES+) M.NH4+ calcd for C19H18NO6SF3, 463; found,
463. HRMS MH+ calcd for C19H18NO6SF3, 446.0885; found, 446.0871.

N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4carboxamide (9j). To a solution of fluorophenylsulfone 10 (3.1 g, 8 mmol) in DMAC (20 mL)
were added Cs2CO3 (8.8 g, 27 mmol) and p-(trifluoromethoxy)phenol (2.1 mL, 16 mmol). The
slurry was stirred at 95°C for 19 h. The reaction was concentrated in vacuo. The residue was
taken up in EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.
Chromatography on silica eluting with EtOAc/hexanes provided the THP-protected hydroxamate
11j as a white foam (4.2 g, 96%). MS (ES+) MH+ calcd for C24H26NO8SF3, 546.14; found,
546.14.

To a slurry of the THP-protected hydroxamate 11j (4.0 g, 7.3 mmol) in 1,4-dioxane (20 mL)
were added a 4N HCl dioxane solution (20 mL) and methanol (20 mL). After 15 minutes at
ambient temperature, the reaction was diluted with EtOAc and washed with water, dried over
Na2SO4, filtered, and concentrated in vacuo. The product was recrystallized (acetone/hexanes) to
give the hydroxamate 9j as a white solid (2.2 g, 65%). 1H NMR (400 MHz, DMSO-d6) δ 10.84
(1H, br s), 9.19 (1H, br s), 7.73 (2H, d, J=8.8 Hz), 7.49 (2H, d, J=8.8 Hz), 7.26-7.43 (2H, m),
7.18 (2H, d, J=9.0 Hz), 3.87 (2H, dd, J=3.8 Hz), 3.16 (2H, t, J=11.6 Hz), 2.22 (2H, d, J=12.9 Hz),
1.89 (2H, td). MS (ES+) M.NH4+ calcd for C19H18NO7SF3, 479.11; found, 479.11. HRMS MH+
calcd for C19H18NO7SF3, 462.0834; found, 462.0815.

N-hydroxy-4-({4-[4-(methylthio)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4carboxamide (9k). To a solution of fluorophenylsulfone 1042 (3.1 g, 8.0 mmol) in DMAC (20
mL) was added Cs2CO3 (7.28 g, 24 mmol) and 4-(methylthio)phenol (2.24 g, 16 mmol). The

slurry was stirred at 95°C for 24 h. The reaction was concentrated in vacuo, and the residue was
taken up in EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo.
Chromatography on silica gel eluting with EtOAc/hexanes provided the diaryl ether 11k as a
white foam (4.1 g, 100%). MS (ES+) calcd for C24H29NO7S2, 208.15; found, 508.15.

To a solution of the THP hydroxamate 11k (4.0 g, 7.9 mmol) in 1,4-dioxane (20 mL) was added
4N HCl in dioxane (20 mL) and methanol (20 mL). After 15 min at rt the reaction was diluted
with EtOAc and washed with water, dried over Na2SO4, filtered and concentrated in vacuo. The
residue was recrystallized (acetone/hexanes) to give the hydroxamate 9k as a white solid (1.9 g,
57%). 1H NMR (400 MHz, DMSO-d6) δ 10.97 (1H, br s), 7.62-7.81 (2H, m) 9.17 (1H, s), 7.327.51 (2H, m), 7.03-7.26 (4H, m), 3.87 (2H, dd, J=3.7 Hz), 3.15 (2H, t, J=11.6 Hz), 2.50 (3H, s),
2.21 (2H, d, J=12.9 Hz), 1.74-2.03 (2H, m). HRMS (ES+) MH+ calcd for C19H21NO6S2 424.09,
found 424.09. HRMS MH+ calcd for C19H21NO6S2 424.0889, found 424.0874.

N-hydroxy-4-[(4-{4-[(trifluoromethyl)thio]phenoxy}phenyl)sulfonyl]tetrahydro-2H-pyran4-carboxamide (9l). To a solution of fluorophenylsulfone 1042 (2.0 g, 5.2 mmol) in DMAC (6
mL) was added 4-(trifluoromethylthio)thiophenol (1.5 g, 7.8 mmol) followed by Cs2CO3 (6.8 g,
20.8 mmol). After adding a catalytic amount of potassium fluoride, the reaction was heated at
95°C for 12 h. The DMAC was removed in vacuo to afford the diaryl ether 11l as a brown solid
(7.2 g, 100%).

To the crude THP-protected diaryl ether 11l (7.2 g, 5.2 mmol) in acetonitrile/water (50 mL) was
slowly added 10% aqueous HCl (100 mL). After stirring for 18h at rt the acetonitrile was

removed in vacuo. The resultant precipitate was collected by filtration to afford hydroxamate
11l as a tan solid (0.60 g, 24%). 1H NMR (400 MHz, DMSO-d6) δ 10.88 - 11.06 (1H, m), 9.19
(1H, d, J=2.0 Hz), 7.63-7.94 (4H, m), 7.16-7.36 (4H, m), 3.88 (2H, dd, J=11.5, 4.3 Hz), 3.053.22 (2H, m), 2.23 (2H, d, J=13.5 Hz), 1.79-1.99 (2H, m). MS (FAB) calcd for C19H18F3NO6S,
476; found, 476. HRMS MH+ calcd for C19H18F3NO6S, 478.0606; found, 478.0615.

4-pyridyl N-hydroxy-4-(4-(pyridin-4-yloxy)phenylsulfonyl)tetrahydro-2H-pyran-4carboxamide(9m). Pyridyloxyphenyl sulfone hydroxamate 9m was prepared from
fluorophenylsulfone 10 according to the general method of 9l to afford the desired hydroxamate
9m as a colorless foam. 1H NMR (400 MHz, DMSO-d6) δ 11.08 (1H, s), 9.25 (1H, d, J=1.9 Hz),
8.12 (2H, d, J=8.2 Hz), 7.78-7.91 (4H, m), 6.29 (2H, d, J=7.8 Hz), 3.89 (2H, dd, J=11.9, 3.7 Hz),
3.17 (2H, t, J=11.7 Hz), 2.24 (2H, d, J=12.9 Hz), 1.89-2.02 (2H, m). HRMS calcd for
C17H18N2O6S, 378.0886; found, 379.0970.

N-hydroxy-4-(4-(4-methoxyphenoxy)phenylsulfonyl)-1-(prop-2-ynyl)piperidine-4carboxamide (19a). To a solution of N-propargyl piperidine 4-fluorophenylsulfone ethyl ester
22a42 (3.00 g, 5.66 mmol) in DMF (10 mL) was added Cs2CO3 (4.7 g, 14.5 mmol) and 4methoxyphenol (1.80 g, 14.5 mmol) and the solution was heated to 95 C for 24 h. The solution
was diluted with EtOAc and washed successively with 1N NaOH and brine, and then dried over
MgSO4. Concentration and chromatographic purification of the residue afforded the
methoxyphenyl ether 20a as a solid (2.67 g, 100%).

To a solution of the phenoxy ether 20a (2.40 g, 5.25 mmol) in ethanol (30 mL) and H2O (6 mL)
was added KOH (2.0 g, 31.37 mmol) and the solution was heated to reflux for 4 h. The solution
was then cooled and acidified with conc HCl to pH = 3, and the resulting precipitate was
collected by vacuum filtration to provide the crude acid 17a that was carried on without
additional purification.

To a solution of the carboxylic acid 17a (2.25 g, 5.25 mmol) in acetonitrile (30 mL) was added
triethylamine (1 mL) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (1.34 g, 9.0 mmol). After
the solution was stirred for 15 min, EDC (1.72g, 9.0 mmol) was added and the solution was
stirred at rt for 18 h. The solution was concentrated in vacuo and the residue was dissolved in
EtOAc and washed successively with saturated aqueous NaHCO3, H2O and brine, and then dried
over MgSO4. After concentration the resulting residue was chromatographed on silica gel
eluting with EtOAc/hexane to afford the THP-protected hydroxamate 18a as a white solid (0.93
g, 33%).

To a solution of the THP-protected hydroxamate 18a (0.93 g, 1.7 mmol) in methanol (15 mL)
was added acetyl chloride (0.36 mL, 5.1 mmol) and the solution was stirred for 3 h. The solution
was concentrated in vacuo to provide the hydroxamate 19a as a white solid (650 mg, 82%). MS
MH+ calcd for C22H24N2O6S, 445; found, 445. Anal calcd for C22H24N2O6S.HCl: C, 54.84; H,
5.24; N, 5.82; S, 6.67; Cl, 6.67. Found: C, 53.10; H, 5.07; 5.59; S, 7.04; Cl, 6.32.

N-hydroxy-4-{[4-(4-methoxyphenoxy)phenyl]sulfonyl}-1-(pyridin-2-ylmethyl)piperidine-4carboxamide (19b). To a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (2.31 g, 4.0

mmol) in 1,4-dioxane (5 mL) was added 4N HCl in 1,4-dioxane (5 mL) and the solution was
stirred for 2 h at rt. The solution was then diluted with ethyl ether and the resulting precipitate
was collected by vacuum filtration to provide the deprotected piperidine hydrochloride salt 21
(2.1 g, 100%). The piperidine hydrochloride salt 21 (2.01 g, 5.76 mmol) was combined with
K2CO3 (2.48 g, 18 mmol), 2-(chloromethyl)pyridine hydrochloride (1.00g, 6.1 mmol), and
DMF(12 mL) and heated at 40°C for 24 h. The mixture was taken up in water (80 mL) and
extracted with EtOAc (3 X 50 mL). The combined organic layer was dried over MgSO4 and
concentrated. The residue was purified by chromatography, the desired N-pyridylmethyl
piperidine 22b (2.30 g, 98%).

The pyridinyl ester 22b (5.66 mmol, 2.30 g), K2CO3 (9.0 mmol, 1.29 g), 4-hydroxyanisole (9
mmol, 1.12 g), and DMF(3 mL) were heated at 75-80°C for 24 h. The reaction was judged to be
incomplete based on TLC, so an additional 350 mg of base and 300 mg of the phenol were
added, and stirring was continued at ambient temperature for 2 d. The reaction was then taken up
in water (50 mL) and extracted with EtOAc (3 X 50 mL). The combined organic layers were
concentrated. The residue was purified by chromatography, affording the diaryl ether 20b as an
oil (2.85 g, 100%).

The ethyl ester 20b (5.7 mmol, 2.85 g) was heated at reflux in the presence of KOH (40 mmol,
2.24 g) in ethanol (18 ml) and water (6 mL) for 4.5 h. The mixture was allowed to cool, was
acidified to ~pH 3 with HCl, and was concentrated and azeotroped to dryness using acetonitrile.
This crude acid (~5.7 mmol) was combined with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (7
mmol, 0.82 g), HOBt (7 mmol, 0.945 g), NMM (1 mL), and EDC (7 mmol, 1.34 g) in the

presence of DMF (21 mL). After 16 h of stirring, the mixture was diluted with 200 mL EtOAc
and was washed with 50% saturated NaHCO3 (100 mL). The aqueous layer was extracted with
additional EtOAc (50 mL), and the combined organic layer was dried over MgSO4.
Concentration and chromatography afforded the desired THP-protected hydroxamate 18b as a
yellow oil (2.82 g, 85 %).

The THP-protected hydroxamate 18b (2.82 g, 5.0 mmol) was dissolved in dry methanol (20 mL).
Acetyl chloride (30 mmol, 2.1 mL) was added over several minutes. The solution was stirred for
4 h at ambient temperature. Concentration afforded 2.59 g of crude product, which was
recrystallized from ethanol/water, yielding the first crop of hydroxamate 19b (525 mg, 18%). MS
(EI) MH+ calcd for C25H27N3O6S 498, found 498. 1H NMR (400 MHz, DMSO-d6) δ 11.16 (1H,
br s), 10.62 (1H, s), 8.66 (1H, d, J=4.3 Hz), 7.87-7.97 (1H, m), 7.72 (2H, d, J=9.0 H), 7.56 (1H,
d, J=7.8 Hz), 7.45-7.52 (1H, m), 7.10-7.19 (2H, m), 7.01-7.10 (4H, m), 4.45 (2H, s), 3.79 (3H,
s), 3.50 (2H, d, J=12.1 Hz), 2.90 (2H, t, J=12.1 Hz), 2.52-2.56 (2H, m), 2.29 (2H, t, J=12.9 Hz).
Anal. calcd for C25H27N3O6S.2HCl.1.5 H2O: C, 50.17; H, 5.18; N, 7.02. Found.: C, 50.45; H,
5.13; N, 7.02. HRMS MH+ calcd for C25H27N3O6S, 498.1699; found, 498.1688.

1-cyclopropyl-4-{[4-(4-ethoxyphenoxy)phenyl]sulfonyl}-N-hydroxypiperidine-4carboxamide (19c). To a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (8.0 g, 19.2
mmol) in DMF (30 mL) was added K2CO3 (4.00 g, 28.8 mmol) and 4-ethoxyphenol (3.99 g, 28.8
mmol). The solution was stirred at 90°C for 24 hours. The solution was diluted with H2O (400
mL) and extracted with EtOAc. The organic layer was washed with brine and dried over
MgSO4, filtered and concentrated in vacuo. Chromatography on silica gel eluting with 10%

EtOAc/hexane provided the desired ester 16c as an oil (9.62 g, 94%). MS MH+ calcd for
C27H35NSO8: 534.2162; found 534.2175. 1H NMR (400 MHz, CDCl3) δ 7.78 (2H, d, J = 6 Hz),
7.01 (2H, d, J = 6 Hz), 6.99 (2H, d, J = 6 Hz), 6.94 (2H, d, J = 6 Hz), 4.21 (2H, q, J = 7 Hz), 4.05
(2H, q, J = 7 Hz), 2.62 (2H, br m), 2.32 (2H, br m), 2.02 (4H, m), 1.46 (9H, s), 1.43 (3H, t, J = 7
Hz), 1.26 (3H, t, J = 7 Hz).

To a solution of N-BOC ethyl ester 16c (9.62 g, 18 mmol) in EtOAc (100 mL) cooled to 0°C was
bubbled gaseous HCl for 5 minutes. The reaction was stirred at this temperature for 0.5 hours.
The solution was then concentrated in vacuo to give the hydrochloride salt (8.1 g, 96%). 1H
NMR (400 MHz, CDCl3) δ 9.71 (2H, br s), 7.70 (2H, d, J = 6 Hz), 7.02 (2H, d, J = 6 Hz), 7.00
(2H, d, J = 6 Hz), 6.94 (2H, d, J = 6 Hz), 4.22 (2H, q, J = 7 Hz), 4.04 (2H, q, J = 7 Hz), 3.64 (2H,
m), 2.85 (2H, m), 2.55 (4H, m), 1.43 (3H, t, J = 7 Hz), 1.26 (3H, t, J = 7 Hz). HRMS MH+ calcd
for C22H27NSO, 434.1637; found, 434.1637. To a solution of the hydrochloride salt (8.1 g, 17.2
mmol) in methanol (70 mL) was added acetic acid (9.86 mL, 172 mmol), a portion of 4Å
molecular sieves (ca. 2 g), (1-ethoxycyclopropyl)-oxytrimethyl silane (20.7 mL, 103 mmol) and
sodium cyanoborohydride (4.86 g, 77.4 mmol), and the solution was refluxed for 8 hours. The
precipitate was removed by filtration and the filtrate was concentrated in vacuo. The residue was
diluted with H2O (400 mL) and extracted with EtOAc. The organic layer was washed with 1 N
NaOH, brine and dried over MgSO4 , filtered and concentrated in vacuo. Trituration with diethyl
ether provided the desired cyclopropyl amine 20c as a white solid (6.84 g, 84%). DSC 146.95150.60°C. 1H NMR (400 MHz, CDCl3) δ 7.68 (2H, d, J = 6 Hz), 7.00 (2H, d, J = 6 Hz), 6.98
(2H, d, J = 6 Hz), 6.92 (2H, d, J = 6 Hz), 4.21 (2H, t, J = 7 Hz), 4.04 (2H, t, J = 7 Hz), 3.05 (2H,

m), 2.32 (2H, m), 2.09 (4H, m), 1.53 (1H, m), 1.43 (3H, t, J = 7 Hz), 1.27 (3H, t, J = 7 Hz), 0.42
(2H, m), 0.37 (2H, m).

To a solution of cyclopropyl amine 20c (6.84 gm, 14.0 mmol) in ethanol (50 mL) and
tetrahydrofuran (50 mL) was added a solution of NaOH (5.60 g, 140 mmol) in water (30 mL)
and the solution was heated at 60°C for 18 hours. The solution was concentrated in vacuo and
the aqueous residue was acidified to pH=3. Filtration gave the carboxylic acid 17c (6.07 g, 88%).
MS MH+ calcd for C22H27NSO6, 446; found, 446. Anal calcd for C23H27NSO6.0.5HCl: C, 59.57;
H, 5.98; N, 3.02. Found: C, 59.33; H, 5.35; N, 2.98.

To a solution of carboxylic acid 17c (6.07 g, 12.6 mmol) in DMF (60 mL) was added 1-HOBt
(2.04 g, 15.1 mmol), NMM (4.15 mL, 37.8 mmol) and O-tetrahydropyranyl hydroxyl amine
(2.21 g, 18.9 mmol) followed by EDC (3.38 g, 17.6 mmol). The solution was stirred at ambient
temperature for 18 hours. The solution was diluted with H2O (400 mL) and extracted with
EtOAc. The organic layer was washed with brine and dried over MgSO4, filtered and
concentrated in vacuo. Chromatography on silica gel eluting with 60% EtOAc/hexane provided
the desired THP-protected hydroxamate 18c as a white foam (6.29 g, 92%). 1H NMR (400 MHz,
CDCl3) δ 9.39 (1H, s), 7.73 (2H, d, J = 6 Hz), 7.02 (2H, d, J = 6 Hz), 6.98 (2H, d, J = 6 Hz), 6.93
(2H, d, J = 6 Hz), 5.01 (1H, t, J = 1 Hz), 4.05 (2H, q, J = 7 Hz), 4.01 (1H, m), 3.70 (1H, m), 3.01
(2H, m), 2.34 (2H, m), 2.14 (4H, m), 1.88 (2H, m), 1.81 (2H, m), 1.60 (2H, ), 1.44 (3H, t, J = 7
Hz), 0.42 (2H, m), 0.37 (2H, m). HRMS MH+ calcd for C28H36N2SO7, 545.2321; found,
545.2316.

To a solution of the THP-protected hydroxamate 18c (2.84 g, 5.0 mmol) in 1,4-dioxane (40 mL)
was added 4 N HCl/dioxane (30 mL). After stirring at ambient temperature for 2.5 hours, the
solution was concentrated in vacuo. Trituration of the resulting solid with diethyl ether and
filtration gave the hydroxamate 19c as a white solid (2.33 g, 90%). DSC 223.15-229.94°C at
442.3 J/g. 1H NMR (400 MHz, DMSO-d6) δ 9.58 (1H, br s), 9.31 (1H, s), 7.70 (2H, d, J = 8.7
Hz), 7.11 (2H, d, J = 7.8 Hz), 7.06 (2H, d, J = 7.8 Hz), 7.06 (2H, d, J = 7.8 Hz), 7.02 (2H, d, J =
8.7 Hz), 4.04 (2H, q, J = 7 Hz), 3.59 (2H, m), 3.28 (2H, m), 2.95 (4H, m), 2.20 (1H, m), 0.97
(2H, m), 0.76 (2H, m). HRMS M+ calcd for C23H28N2SO6, 460.1677; found, 460.1678. Anal
calcd for C23H28N2SO6.HCl: C, 55.58; H, 5.88; N, 5.64; Cl, 7.13; S, 6.45. Found: C, 55.22; H,
5.73; N, 5.59; Cl, 7.49; S, 6.64.

N-hydroxy-4-{[4-(4-isopropylphenoxy)phenyl]sulfonyl}-1-prop-2-yn-1-ylpiperidine-4carboxamide (18d). To a solution of N-propargyl ethyl ester p-fluorosulfone 22d42 (6.0 g, 15.4
mmol) in DMF (70 mL) was added powdered K2CO3 (8.0 g, 38.5 mmol) and 4-isopropyl phenol
(5.24 g, 38.5 mmol) and the solution was heated to 90°C for 32 h. The reaction mixture was then
concentrated under high vacuum and the residue was then partitioned between EtOAc and water.
The organic layer was washed successively with 1N aqueous NaOH and water and then
concentrated to give a residue that was chromatographed on silica gel eluting with
EtOAc/hexane to provide the diaryl ether 20d as a light yellow gel (6.89 g, 87%).

To a solution of the diaryl ether ethyl ester 20d (6.89 g, 14.7 mmol) in ethanol (14 mL) and THF
(14 mL) was added a solution of NaOH (5.88 g, 147 mmol) in water (28 mL) via an addition
funnel at rt. The solution was then heated to 60°C. Concentration in vacuo gave a residue which

was diluted with water, washed with ether, and then acidified to pH = 2 with concentrated
aqueous HCl. The resulting precipitate was collected via filtration to afford the carboxylic acid
17d as a white solid (6.56 g, 100%).

To a solution of carboxylic acid 17d (6.56 g, 14.86 mmol), NMM (6.5 mL, 59.4 mmol) HOBt
(6.0 g, 44.6 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (3.5 g, 29.7 mmol) in DMF
(50 mL) was added EDC (8.5 g, 44.6 mmol) and the solution was stirred at rt for 20 h. The
reaction mixture was then concentrated under high vacuum and the residue was partitioned
between water and EtOAc. The organic layer was washed with saturated aqueous NaHCO3 and
water and dried over MgSO4. Concentration in vacuo and chromatography on silica gel eluting
with EtOAc/hexane provided the THP-protected hydroxamate 18d as a white foam (8.03 g,
100%).

To a solution of THP-protected hydroxamate 18d (8.03 g, 14.9 mmol) in methanol (5 mL) and
1,4-dioxane (15 mL) was added a 4N solution of HCl in 1,4-dioxane (37 mL, 149 mmol) and the
solution was stirred at rt for 3 h. Concentration and trituration of the residue with diethyl ether
provided the N-propargyl piperidine hydroxamate 19d (5.0 g, 71.1%) as a white solid. 1H NMR
(400 MHz, DMSO-d6) δ 11.15 (1H, br s), 7.73 (2H, d, J=9.0 Hz) 9.36 (1H, s), 7.37 (2H, d, J=8.6
Hz), 7.11 (4H, dd, J=8.8, 3.3 Hz), 4.01-4.15 (2H, m), 3.79-3.91 (1H, m), 3.49-3.66 (2H, m),
2.88-3.02 (1H, m), 2.71-2.85 (2H, m), 2.60 (2H, s), 2.11-2.28 (2H, m), 1.24 (3H, s), 1.22 (3H, s).
Anal. calcd for C24H28N2O5S.HCl.0.9H2O: C, 56.61; H, 6.10; N, 5.50; S, 6.30. Found: C,
56.97; H, 6.05; N, 5.41; S, 5.98. HRMS MH+ calcd for C24H28N2O5S, 457.1797; found,
457.1816.

N-hydroxy-4-{[4-(4-isopropylphenoxy)phenyl]sulfonyl}-1-(2-methoxyethyl)piperidine-4carboxamide (19e). Hydroxamate 19e was prepared according to the general method illustrated
for 19d to afford N-methoxyethyl 4-isopropylphenyloxyphenylsulfone hydroxamate 19e: 1H
NMR (400 MHz, DMSO-d6) δ 11.18 (1H, br s), 9.32 (1H, br s), 7.74 (2H, d, J=9.0 Hz), 7.37
(2H, d, J=8.6 Hz), 7.11 (4H, dd, J=8.8, 6.8 Hz), 3.54-3.64 (4H, m), 3.22-3.30 (5H, m), 2.89-2.99
(m), 2.71-2.83 (2H, m), 2.52-2.58 (2H, m), 2.17-2.30 (2H, m), 1.24 (3H, s), 1.22 (3H, s). HRMS
MH+ calcd for C24H32N2O6S, 477.2059; found, 477.2073.

N-hydroxy-1-isopropyl-4-{[4-(4-isopropylphenoxy)phenyl]sulfonyl}piperidine-4carboxamide (19f). To a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (30 g, 161
mmol) in dichloromethane (40 mL) cooled to 0°C was added trifluoroacetic acid (30 mL) and the
solution was stirred at rt for 1 h. Concentration in vacuo provided the trifluoroacetate salt as a
light yellow oil. To the solution of the trifluoroacetate salt and triethylamine (28 mL, 201 mmol)
in dichloromethane (250 mL) cooled to 0°C were added acetone (24 mL, 320 mmol) and sodium
triacetoxyborohydride (68 g, 201 mmol) in small portions followed by addition of acetic acid
(18.5 mL, 320 mmol), and the solution was stirred at rt for 48 h. The reaction mixture was
concentrated and the residue diluted with diethyl ether and washed with 1N aqueous NaOH and
water and dried over MgSO4. Concentration in vacuo provided the N-isopropyl amine 22f as a
light yellow oil.

To a solution of N-isopropyl piperidine 22f (4.0 g, 11.2 mmol) and powdered K2CO3 (3.909 g,
22.4 mmol) in DMF (30 mL) was added 4-isopropylphenol (3.05 g, 22 mmol) and the solution

was heated to 90°C for 25 h. Concentration under high vacuum afforded a residue which was
dissolved in EtOAc. This organic phase was washed with 1N aqueous NaOH, water and dried
over MgSO4. Chromatography on silica gel eluting with EtOAc/hexane provided the desired
diaryl ether 20f as a light yellow gel (5.10 g, 96.2%).

To a solution of diaryl ether ethyl ester 20f (5.10 g, 10.77 mmol) in ethanol (10 mL) and THF
(10 mL) was added a solution of NaOH (4.3 g, 108 mmol) in water (20 mL) and the solution was
heated to 60°C for 24 H. Concentration afforded a residue which was dissolved in water. This
aqueous phase was washed with diethyl ether and then acidified with concentrated HCl to pH=2.
Vacuum filtration of the resulting precipitate provided carboxylic acid 17f (4.80 g, 100%) as a
white solid.

To a solution of carboxylic acid 17f (4.80 g, 10.8 mmol), NMM (3.6 mL, 32.4 mmol), HOBt (4.4
g, 32.4 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (2.6 g, 21.6 mmol) in DMF (100
mL) was added EDC (6.17 g, 32.4 mmol) and the solution was stirred at rt for 7 d. The mixture
was filtered to remove unreacted starting material and the filtrate was concentrated under high
vacuum. The residue was dissolved in EtOAc and this organic phase was washed with saturated
aqueous NaHCO3, water and dried over MgSO4. Concentration in vacuo and chromatography
on silica gel eluting with EtOAc/hexane provided the THP-protected hydroxamate 18f (2.45 g,
41.7%) as a white foam.

To a solution of THP-protected hydroxamate 18f in methanol (4 mL) and 1,4-dioxane (8 mL)
was added a 4N solution of HCl in 1,4-dioxane (11.2 mL, 45 mmol) and the solution was stirred

at rt for 3h. Concentration in vacuo gave a residue which was triturated with diethyl ether to
provide N-isopropyl piperidine hydroxamate 19f (2.01 g, 89.7%) as a white solid: 1H NMR (400
MHz, DMSO-d6) δ 11.21 (1H, br s), 9.29 (1H, s), 7.73 (2H, d, J=8.6 Hz), 7.36 (2H, d, J=8.6 Hz),
7.12 (4H, t, J=9.0 Hz), 3.49-3.62 (2H, m), 3.36-3.48 (3H, m), 2.87-3.00 (1H, m), 2.52-2.70 (2H,
m), 2.17-2.31 (2H, m), 1.24 (3H, s), 1.22 (3H, s), 1.21 (3H, s), 1.19 (3H, s). HRMS calcd for
C24H32N2O5S, 461.2110; found, 461.2108. Anal. calcd for C24H32N2O5S.HCl.0.5H2O: C, 56.96;
H, 6.77; N, 5.54; S, 6.34. Found: C, 56.58; H, 6.71; N, 5.44; S, 6.25.

N-hydroxy-4-{[4-(4-isopropoxyphenoxy)phenyl]sulfonyl}-1-(2-methoxyethyl)piperidine-4carboxamide (19g). To a solution of N-methoxyethyl-piperidine ethyl ester p-flourosulfone 22g
(2.0 g, 5.4 mmol) in DMF (20 mL) were added 4-isopropoxyphenol65 (1.63 g, 10.7 mmol) and
Cs2CO3 (7 g, 21.5 mmol) and the resulting suspension was heated to 60°C for 16 h. The reaction
mixture was then concentrated in vacuo. The residue was dissolved in EtOAc and washed with
1N NaOH, water and brine and dried over MgSO4. Concentration of the organic phase gave a
residue that was purified by chromatography on silica gel eluting with EtOAc/hexane to afford
the desired diaryl ether 20g (1.37 g, 50%).

To a solution of ethyl ester diaryl ether 20g (1.37 g, 2.7 mmol) in ethanol (30 mL) and water 30
mL) and water (30 mL) was added NaOH (1.08 g, 27 mmol) and the mixture was heated to 65°C
for 16 h. The solvents were removed in vacuo. Water (50 mL) was added and the mixture was
again concentrated in vacuo and the resulting mixture was acidified with 2N HCl to pH = 4-5.
The resulting precipitate was collected by filtration and rinsed with diethyl ether to afford
carboxylic acid 17g (1.25 g, 100%).

To a suspension of carboxylic acid 17g (1.25 g, 2.7 mmol) in DMF (15 mL) were added NMM
(0.82 g, 8.1 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (0.61 g, 4.1 mmol) followed by
bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP, 1.51 g, 3.3 mmol). After
stirring for 16 h at rt the reaction was concentrated to a residue that was dissolved in EtOAc and
washed with water and brine. Concentration and purification by chromatography on silica gel
eluting with EtOAc/hexane afforded the THP-protected hydroxamate 18g (1.0 g, 63%) as a white
solid.

Through a solution of the THP-protected hydroxamate 18g (1.0 g, 1.7 mmol) in EtOAc (20 mL)
was bubbled HCl gas for 5 min. After stirring at rt for an additional 5 h, the solvent was
removed in vacuo. EtOAc (30 mL) was added and then removed in vacuo. EtOAc (30 mL) was
again added and the resulting solid was collected by filtration to afford the N-methoxyethyl
piperidine hydroxamate hydrochloride salt 19g (0.50 g, 56%) as a white solid: 1H NMR (400
MHz, DMSO-d6) δ 11.17 (1H, br s), 9.32 (1H, br s), 7.72 (2H, d, J=9.0 Hz), 7.06-7.16 (4H, m),
6.98-7.06 (2H, m), 4.51-4.67 (1H, m), 3.51-3.67 (4H, m), 3.20-3.32 (5H m), 2.69-2.84 (2H, m),
2.50-2.59 (2H, m), 2.15-2.30 (2H, m), 1.29 (3H, s), 1.28 (3H, s). Anal. calcd for
C24H32N2O7S.HCl.1.5H2O: C, 51.84; H, 6.53; N, 5.04; Cl, 6.38; S, 5.77. Found: C, 51.87; H,
6.12; N, 4.92; Cl, 6.38; S, 5.84. MS MH+ calcd for C24H32N2O7S 493, found 493. HRMS calcd
for C24H32N2O7S, 493.2008; found, 493.1992.

1-cyclopropyl-N-hydroxy-4-{[4-(4-isopropoxyphenoxy)phenyl]sulfonyl}piperidine-4carboxamide (19h).

To a solution of N-cyclopropyl 4-fluorosulfone ethyl ester 22h (2.49 g, 7.0 mmol) in DMAC (30
mL) were added 4-isopropoxyphenol65 (1.28 g, 8.4 mmol) and Cs2CO3 (5.48 g, 16.8 mmol), and
the resulting suspension was heated at 60°C for 16 h. The reaction mixture was then concentrated
in vacuo. The residue was dissolve in EtOAc and washed with 1 N NaOH, water and brine.
Concentration of the organic phase gave a residue which was purified by chromatography on
silica gel eluting with EtOAc/hexane to afford aryl ether 20h (2.8 grams, 82%).

To a solution of the ethyl ester 20h (2.8 g, 5.7 mmol) in ethanol (50 mL) and water (50 mL) was
added NaOH (2.3 g, 57 mmol) and the mixture was heated to 60°C for 16 hours. The solvents
were removed in vacuo. Water (50 mL) was added and the mixture was acidified with 2 N HC1
to pH = 4. The resulting precipitate was collected by filtration to afford carboxylic acid 17h (1.4
g, 53%).

To a solution of carboxylic acid 17h (1.4 g, 3.1 mmol) in DMF(15 mL) were added NMM (0.92
g, 9.1 mmol), HOBt (0.49 g, 3.66 mmol), and EDC (0.82 g, 4.26 mmol) followed by O(tetrahydro-2H-pyran-2-yl) hydroxylamine (0.68 g, 4.5 mmol). After stirring for 16 hours at
ambient temperature, the reaction mixture was concentrated to a residue that was dissolve in
EtOAc and washed with water and brine. Concentration and purification by chromatography on
silica gel, eluting with EtOAc/hexane, afforded THP-protected hydroxamate 18h.

To a solution of protected hydroxamate 18h in methanol/1,4-dioxane (1:3, 20 mL) was added 4
N HC1/1,4-dioxane (10 mL) and the solution was stirred at ambient temperature for 3 h. The

solvent was then removed in vacuo. An additional portion of EtOAc was added and then
removed in vacuo. Diethyl ether was added and the resulting solid was collected by filtration to
afford hydroxamate 19h (0.3 g, 19%). 1H NMR (400 MHz, DMSO-d6) δ 11.19 (1H, br s), 9.34
(1H, br s), 7.70 (2H, d, J=8.6 Hz), 7.09 (4H, d), 6.99-7.04 (2H, m), 4.57-4.65 (1H, m), 2.87-3.06
(3H, m), 2.52-2.60 (2H, m), 2.09-2.25 (3H, m), 1.29 (3H, s), 1.28 (3H, s), 0.91 - 0.98 (2H, m),
0.74-0.79 (2H, m). Anal. calcd for C24H30N206S.HC1: C, 56.41; H, 6.11; N, 5.48. Found:
C, 56.04; H, 5.82; N, 5.44. MS (CI) MH+ calcd for C24H30N206S, 475; found. 475. HRMS MH+
calcd for C24H30N206S, 475.1903; found, 475.1893.

N-hydroxy-4-(4-(4-(methylsulfonyl)phenoxy)phenylsulfonyl)-1-(prop-2-ynyl)piperidine-4carboxamide (19i). To a solution of N-propargyl ethyl ester p-fluorosulfone 22i42 (2.5 g, 6.4
mmol) in DMF (15 mL) were added 4-methylsulfonylphenol (3.5 g, 20.3 mmol) and Cs2CO3 (8.7
g, 27 mmol) and the resulting suspension was heated to 90°C for 16 h. The reaction mixture was
then concentrated in vacuo. The residue was dissolved in EtOAc (500 mL) and washed with 1N
NaOH, water and brine. Concentration of the organic phase gave a residue which was purified
by chromatography on silica gel eluting with EtOAc/hexane (1;1) to afford diaryl ether 20i (2.5
g, 77%).

To a solution of the diaryl ether ethyl ester 20i (2.5 g, 4.9 mmol) in ethanol (50 mL) and water
(30 mL) was added NaOH (2.0 g, 49 mmol) and the mixture was heated to 65°C for 8 h. The
solvents were removed in vacuo. Water (50 mL) was added, the mixture was again concentrated
in vacuo and the resulting mixture was acidified with 2N HCl to pH = 4-5. The resulting
precipitate was collected by filtration to afford carboxylic acid 17i (1.57 g, 67%).

To a solution of carboxylic acid 17i (1.57 g, 3.3 mmol) in DMF (15 mL) were added NMM (0.5
g, 4.9 mmol), HOBt (0.53 g, 3.9 mmol), and EDC (0.88 g, 4.6 mmol) followed by O-(tetrahydro2H-pyran-2-yl)hydroxylamine (0.74 g, 4.9 mmol). After stirring for 16 h at rt the reaction
mixture was concentrated to a residue that was dissolved in EtOAc (200 mL) and washed with
water and brine. Concentration and purification by chromatography on silica gel eluting with
EtOAc/hexane afforded THP-protected hydroxamate 18i (1.5 g, 79%) which was used directly.

To a solution of THP-protected hydroxamate 18i (1.5 g, 2.60 mmol) in methanol/1,4-dioxane
(1:3, 40 mL) was added 4N HCl/1,4-dioxane (10 mL) and the solution was stirred at rt for 3 h.
The solvent was then removed in vacuo. Methanol (30 mL) was added and then removed in
vacuo. Diethyl ether (100 mL) was added and the resulting solid was collected by filtration to
afford hydroxamate 19i (1.35 g, 98%) as a colorless solid: 1H NMR (400 MHz, DMSO-d6) δ
11.19 (1H, br s), 9.41 (1H br s), 8.01 (2H, d, J=9.0 Hz), 7.82 (d, J=9.0 Hz), 7.40 (2H, d, J=8.6
Hz, 2 H), 7.33 (2H, d, J=8.6 Hz), 3.98-4.14 (2H, m), 3.76-3.89 (1H, m), 3.51-3.64 (2H, m), 3.45
(3H, br s), 2.72-2.86 (2H, m), 2.53-2.64 (2H, m), 2.19-2.31 (2H, m). Anal. calcd for
C22H24N2O7S2.HCl: C, 49.95; H, 4.76; N, 5.30; Cl, 6.70; S, 12.12. Found C, 49.78; H, 4.56; N,
5.25; Cl, 6.98; S, 11.98. HRMS (ESI) MH+ calcd for C22H24N2O7S2, 493.1103; found, 493.1106.

4-(4-(benzo[d][1,3]dioxol-5-yloxy)phenylsulfonyl)-N-hydroxypiperidine-4-carboxamide
(19j). To a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (25.0 g, 67.3 mmol) and
powdered K2CO3 (23.3 g, 16.9 mmol) in DMF was added sesamol (23.24 g, 16.8 mmol) at rt and
the solution was heated to 90°C for 24 h. The solution was concentrated and then dissolved in

EtOAc. The organic layer was washed successively with 1N NaOH and water and then dried
over MgSO4. Concentration gave a residue which was chromatographed on silica gel eluting
with EtOAc/hexane to provide N-BOC diaryl ether 16j as a white foam (33.6 g, 93.6%).

To a solution of ethyl ester 16j (29.31 g, 54.93 mmol) in ethanol (60 mL) and THF (60 mL) was
added NaOH (21.97 g, 544 mmol) over 20 min at rt. The solution was then heated to 60°C for 9
h. The reaction mixture was then concentrated and diluted with water and extracted with diethyl
ether, and then acidified to pH=2. The mixture was then extracted with EtOAc. The combined
organic layers were washed with water and dried over MgSO4. Concentration gave carboxylic
acid 17j as a white solid (25.3 g, 91.0%).

To a solution of N-BOC-piperidine carboxylic acid 17j (1.25 g, 2.47 mmol), NMM (1.00 g, 9.89
mmol) and HOBt (0.40 g, 2.96 mmol) in DMF (6 mL) was added solid EDC (0.616 g, 3.21
mmol) followed by a solution of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in DMF (2 mL).
After stirring for 2 d at rt the pale yellow solution was concentrated in vacuo, then dissolved in
EA and washed successively with water (3 X 40 mL) and brine (30 mL). The solution was dried
over Na2SO4 and concentrated to give THP-protected hydroxamate 18j as a nearly colorless
foam (1.54 g, 100%): DSC 221.01°C. MIR ν 32 85, 1693, 1478 cm-1.

To a solution of THP-protected hydroxamate 18j (1.49 g, 2.46 mmol) in 1,4-dioxane (9 mL) and
methanol (3 mL) was added 4N HCl in dioxane (10 mL, 40 mmol). After 1.5 h at rt the
suspension was treated with diethyl ether (15 mL) and filtered to afford hydroxamic acid 19j
(1.00 g, 89%) as a colorless powder. DSC 255.96C; IR ν 3213, 3107, 1653, 1144 cm-1; MS

MH+ calcd for C19H20N2O7S, 421; found, 421; C19H20N2O7S, 49.95; H, 4.73; N, 6.13; Cl, 7.76; S,
7.02. Found C, 49.82; H, 4.60; N, 5.98; Cl, 17.38; S, 7.10.

4-{[4-(1,3-benzodioxol-5-yloxy)phenyl]sulfonyl}-N-hydroxy-1-prop-2-yn-1-ylpiperidine-4carboxamide (19k). To 4-(4-fluorobenzenesulfonyl)-1-prop-2-ynyl-piperidine-4-carboxylic
acid ethyl ester 22k (19.8 mmol, 7.00 g) was added 1,3-benzodioxol-5-ol (40 mmol, 5.52 g),
K2CO3 (40 mmol, 5.52 g), and DMF(30 mL). The mixture was heated at 80°C for 48 h. The
mixture was then partitioned between EtOAc (200 mL) and water (150 mL). The aqueous phase
was extracted with additional EtOAc (2 X 100 mL). The combined organic phases were dried
over MgSO4, then filtered through silica, and concentrated. Chromatography afforded diaryl
ether 20k as an oil (9.38 g, 100%). Elem. Anal. calcd for C24H25NO7S: C, 61.13; H, 5.34; N,
2.97. obsd C, 61.02; H, 5.44; N, 2.72.

Ethyl ester 20k (2.72 g, 5.92 mmol) was combined with ethanol (30 mL), water, (5 mL) and
potassium hydroxide (2.0g, 36 mmol) and stirred for 1 h at ambient. Reaction was incomplete, so
the mixture was heated at reflux for 4 h. The mixture was allowed to cool and was acidified to
~pH 3 using conc. HCl. Concentration following by azeotropic drying with acetonitrile afforded
crude carboxylic acid 17k, which was used without purification.

To carboxylic acid 17k was added O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (9 mmol, 1.053
g) and acetonitrile (30 mL). Triethylamine (1 mL) was added, followed by EDC (9 mmol, 1.72
g). The mixture was stirred for 16 h and worked up using half-saturated NaHCO3 (20 mL) and

EtOAc (2 X 50 mL). The combined organic phase was dried over MgSO4, concentrated and
chromatographed, affording THP-protected hydroxamate 18k (2.86 g, 89%).

The THP-protected hydroxamate 18k (5.27 mmol, 2.86 g) was diluted with methanol (40 mL)
and lowered into a water bath. Acetyl chloride (1.14 mL, 15.8 mmol) was added over 1 minute.
After stirring at ambient temperature for 3 h, the mixture was concentrated and azeotroped 5
times with chloroform to afford 2.42 g white solid was obtained, of which 1 g (41%) was
purified by reverse-phase chromatography on a C-18 column eluting with15% acetonitrile, 85%
0.1N HCl. Concentration of the eluent gave hydroxamate 19k (1.0 g, 97%) as a white solid. 1H
NMR (400 MHz, DMSO-d6) δ 11.14 (1H, br s), 9.36 (1H, s), 7.72 (2H, d, J=9.0 Hz), 7.11 (2H, d,
J=9.0 Hz), 7.00 (1H, d, J=8.6 Hz), 6.88 (1H, d, J=2.3 Hz), 6.65 (1H, dd, J=8.6, 2.3 Hz), 3.984.18 (2H, m) 6.10 (2H, s), 3.79-3.90 (1H, m), 3.50-3.68 (2H, m), 2.69-2.87 (2H, m), 2.52-2.62
(2H, m), 2.11-2.28 (2H, m). MS (CI) MH+ calcd for C22H22N2O7S, 459; found, 459. HRMS
calcd for C22H22N2O7S, 459.1226; found, 459.1222. Anal. calcd for C22H22N2O7S.HCl.1.5 H2O:
C, 51.56; H, 5.07; N, 5.47. Found: C, 51.54; H, 4.55; N, 5.64.

4-{[4-(1,3-benzodioxol-5-yloxy)phenyl]sulfonyl}-N-hydroxy-1-(2-methoxyethyl)piperidine4-carboxamide (19l). To a solution of N-BOC ethyl ester diaryl ether 16l (4.0 g, 7.4 mmol) in
dichloromethane (7 mL) at 0°C was added trifluoroacetic acid (7 mL) and the solution was
stirred a rt for 2 h. Concentration in vacuo provided the piperidine trifluoroacetate salt as a light
yellow gel. To a solution of the trifluoroacetate salt in DMF (50 mL) was added K2CO3 (3.6 g,
26 mmol) and 2-bromoethyl methyl ether (1.8 mL, 18.7 mmol) and the solution was stirred at rt
for 36 h. The DMF was evaporated under high vacuum and the residue was diluted with EtOAc.

This organic phase was then washed with water and brine and dried over MgSO4. Concentration
in vacuo provided the N-methoxyethyl-piperidine 20l as a light yellow oil (3.7 g, 100%).

To a solution of the ethyl ester 20l in ethanol (7 mL) and THF (7 mL) was added a solution of
NaOH (3.0 g, 75 mmol) in water (15 mL) and the solution was heated to 60°C for 19 h. The
solution was then concentrated in vacuo and diluted with water. This aqueous phase was washed
with ether and then acidified to pH=2. Vacuum filtration of the white precipitate provided
carboxylic acid 17l as a white solid (4.0 g, 100%).

To a solution of carboxylic acid 17l (4.0 g, 7.5 mmol) NMM (3.3 mL, 30 mmol), HOBt (3.0 g,
22.5 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (1.8 g, 15 mmol) in DMF (100
mL) was added EDC (4.3 g, 22.5 mmol) and the solution was stirred at rt for 4 d. The reaction
mixture was then concentrated under high vacuum and the residue was dissolved in EtOAc. This
organic phase was washed with saturated aqueous NaHCO3 and water and dried over MgSO4.
Concentration in vacuo and chromatography of the residue on silica gel eluting with
EtOAc/hexane provided the THP-protected hydroxamate 18l as a white foam (2.40 g, 57.1%).

To a solution of THP-protected hydroxamate 18l (2.4 g, 4.3 mmol) in methanol (2 mL) and 1,4dioxane (6 mL) was added a 4N solution of HCl in 1,4-dioxane (11 mL, 43 mmol). The solution
was stirred at rt for 3 h. Concentration in vacuo and trituration of the residue with ether provided
the N-methoxyethyl piperidine hydroxamate 19l (1.88 g, 85.8%) as a white solid: 1H NMR (400
MHz, DMSO-d6) δ 11.18 (1H, br s), 9.33 (1H, br s), 7.72 (2H, d, J=9.0 Hz), 7.11 (2H, d, J=9.0
Hz), 7.01 (1H, d, J=8.6 Hz), 6.87 (1H, d, J=2.7 Hz), 6.64 (1H, dd, J=8.6, 2.3 Hz), 6.10 (2H, s),

3.52-3.67 (2H, m), 3.34-3.43 (2H, m), 3.19-3.31 (5H, m), 2.71-2.85 (2H, m), 2.53-2.59 (2H, m),
2.13-2.28 (2H, m). Anal. calcd for C22H26N2O8S.HCl.H2O: C, 49.58; H, 5.48; N, 5.26; S, 6.02.
Found C, 49.59; H, 5.53; N, 5.06; S, 5.71. HRMS MH+ calcd for C22H26N2O8S, 479.1488;
found, 479.1497.

4-(4-(benzo[d][1,3]dioxol-5-yloxy)phenylsulfonyl)-1-cyclopropyl-N-hydroxypiperidine-4carboxamide (19m). To a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (9.0 g,
22.0 mmol) in DMF (30 mL) was added K2CO3 (4.55 g, 33 mmol) and sesamol (4.55 g, 33
mmol). The solution was stirred at 90°C for 24 H. The mixture was diluted with H2O (400 mL)
and extracted with EtOAc. The organic layer was washed with brine and dried over MgSO4,
filtered and concentrated in vacuo. Chromatography on silica gel eluting with EtOAc/hexane
(10/90) provided diaryl ether 16m as an oil (9.3 g, 79%). 1H NMR (CDCl3, 400 MHz) δ 7.69
(2H, d, J = 7 Hz), 7.01 (2H, d, J = 7 Hz), 6.60 (1H, s), 6.55 (1H, d, J = 7 Hz), 6.02 (2H, s), 4.20
(2H, q, J = 7 Hz), 4.19 (4h, br m), 2.72 (2H, br m), 2.32 (2H, br m), 1.45 (9H, s), 1.26 3H, t, J =
7 Hz). HRMS MH+ calcd for C26H31NSO9, 534.1798; found, 534.1796.

Through a solution of ethyl ester 16m (9.3 g, 17 mmol) in EtOAc (100 mL) cooled to 0°C was
bubbled HCl gas for 10 min. The reaction was stirred for an additional 0.5 h at 0°C.
Concentration afforded the piperidine hydrochloride salt (7.34 g, 92%) as a white solid. 1H
NMR (400 MHz, CDCl3) δ 9.60 (2H, br s), 7.71 (2H, d, J = 6 Hz), 7.04 (2H, d, J = 6 Hz), 6.82
(1H, d, J = 6 Hz), 6.62 (1H, s), 6.57 (1H, d, J = 6 Hz), 6.03 (2H, s), 4.22 (2H, q, J = 7 Hz), 3.63
(2H, m), 2.83 (2H, br m), 2.53, 4H, br m), 1.26 (3H, t, J = 7 Hz). HRMS MH+ calcd for
C21H23NSO7, 434.1273; found, 434.1285. To a solution of this hydrochloride salt (7.34 g, 15.6

mmol) in methanol (60 mL) was added acetic acid (8.94 mL, 156 mmol), a portion of 4A
molecular sieves (2 g), (1-ethoxycyclopropyl)-oxytrimethylsilane (18.8 mL, 93.6 mmol) and
sodium cyanoborohydride (4.41 g, 70.2 mmol). The reaction was heated under reflux for 8 h.
Upon cooling the precipitate was removed by filtration and the filtrate was concentrated in
vacuo. The residue was partitioned between water and EtOAc. The organic layer was washed
with brine and dried over MgSO4, filtered and concentrated in vacuo. Chromatography on silica
gel eluting with EtOAc provided N-cyclopropyl amine 20m (7.9 g, 100%) as a white solid: 1H
NMR (400 MHz, CDCl3) δ 7.69 (2H, d, J = 7 Hz), 7.00 (2H, d, J = 7 Hz), 6.82 (1H, d, J = 7 Hz),
6.60 (1H, d, J = 7 Hz), 6.55 (1H, d, J = 7 Hz), 6.02 (2H, s), 4.21 (2H, q, J = 7 Hz), 3.10 (2H, m),
2.31 (2H, m), 2.09 (4H, m), 0.94 (1H, m), 0.40 (4H, m). HRMS MH+ calcd for C24H27NSO7,
474.1586; found, 474.1599.

To a solution of the N-cyclopropyl piperidine ethyl ester 20m (7.9 g, 16.7 mmol) in ethanol (50
mL) and THF (50 mL) was added a solution of NaOH (6.68 g, 166.8 mmol) in water (30 mL)
and the solution was heated to 60°C for 18h. The solution was then concentrated in vacuo and
the aqueous remnant was acidified to pH=3 with concentrated aqueous HCl. The resulting
precipitate was filtered to give carboxylic acid 17m (6.14 g, 76%) as a colorless solid: HRMS
MH+ calcd for C22H25NSO7, 446.1273; found, 446.1331.

To a solution of carboxylic acid 17m (6.14 g, 12.7 mmol) in DMF (60 mL) was added HOBt
(2.06 g, 15.2 mmol), NMM (4.2 mL, 38.0 mmol) and O-(tetrahydro-2H-pyran-2yl)hydroxylamine (2.23 g, 19.0 mmol) followed by EDC (3.41 g, 17.8 mmol). The solution was
stirred at rt for 18 h. The solution was then cooled and diluted with water (400 mL) and

extracted with EtOAc. The organic layer was washed with brine and dried over MgSO4, filtered
and concentrated in vacuo. Chromatography on silica gel eluting with EtOAc/hexane (40/60)
provided the THP-protected hydroxamate 18m (6.67 g, 96%) as a colorless solid.

To a solution of THP-protected hydroxamate 18m (6.67 g, 12.0 mmol) in 1,4-dioxane (70 mL)
was added 4N HCl in 1,4-dioxane (6.6 mL). After stirring at rt for 3 h the solution was
concentrated in vacuo. Chromatography on a C18 reverse-phase column eluting with
acetonitrile/(HCl)water provided the desired hydroxamate 19m (4.21 g, 69%) as a white solid.
DSC 188.76-198.88°C. 1H NMR (400 MHz, CDCl3) δ 11.17 (1H, s), 10.18 (1H, br s), 9.31 (1H,
s), 7.71 (2H, d, J = 7 Hz), 7.10 (2H, d, J = 7 Hz), 6.99 (1H, d, J = 7 Hz), 6.88 (1H, s), 6.66 (1H,
d, J = 7 Hz), 6.09 (2H, s), 3.55 (2H, br m), 3.00-2.83 (4H, br m), 2.26 (2H, br m), 1.02 (2H, m),
0.74 (2H, m). HRMS MH+ calcd for C22H24N2SO7, 461.1382; found, 461.1386. Anal. calcd for
C22H24N2SO7.HCl C, 53.17; H, 5.07; N, 5.64; Cl, 7.14; S, 6.45. Found C, 52.97; H, 5.03; N,
5.63, Cl, 6.99; S, 6.78.

1-cyclopropyl-4-{[4-(2,3-dihydro-1,4-benzodioxin-6-yloxy)phenyl]sulfonyl}-Nhydroxypiperidine-4-carboxamide (19n). To a solution of 4-fluorophenyl sulfone piperidine
hydrochloride 2142 (14.36 g, 40 mmol) in methanol (50 mL) was added acetic acid (24.5 g, 400
mmol), a portion of 4A molecular sieves (2 g), (1-ethoxycyclopropyl)-oxytrimethylsilane (25.8
mL, 148 mmol) and sodium cyanoborohydride (7.l05 g, 112 mmol). The solution was heated
under reflux for 8 h. The reaction was allowed to cool and the precipitated solids were removed
by filtration and the filtrate was concentrated in vacuo. The residue was diluted with water (400
mL) and extracted with EtOAc. The organic layer was washed with brine and dried over

MgSO4, filtered, and concentrated in vacuo to give the N-cyclopropyl piperidine 22n as a
colorless solid (11.83 g, 81.5%). MS MH+ calcd for C17H22NO4SF3, 356; found, 356.

To a solution of the N-cyclopropyl amine ethyl ester p-fluoro sulfone 22n (1.36 g, 3.47 mmol) in
DMF (8 mL) was added 6-hydroxybenzo-1,4-dioxane (792 mg, 5.21 mmol) followed by Cs2CO3
(2.83 g, 8.69 mmol) and the solution was heated to 100°C for 20 h. The solution was then
cooled and partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc
and the combined organic extracts were washed with water and brine and dried over Na2SO4.
Filtration through a pad of silica gel eluting with EtOAc/hexane provided the diaryl ether ethyl
20n an orange oil (1.81 g, 100%). MS(CI) MH+ calcd for C25H29NO7S, 488; found, 488.

To a solution of the ethyl ester 20n (1.81 g) in THF (10 mL) and ethanol (10 mL) was added
sodium hydroxide (1.39 g, 34.7 mmol) in water (5 mL). The solution was heated to 60°C for 20
h. The solution was then concentrated in vacuo and the aqueous residue acidified to pH=2 with
10% aqueous HCl. The resulting solid was collected by vacuum filtration to provide carboxylic
acid 17n as a yellow solid (1.23 g, 72%). HRMS(CI) MH+ calcd for C23H25NO7S, 460.1430;
found, 460.1445.

To a suspension of carboxylic acid 17n (1.21 g, 2.46 mmol) in DMF (20 mL) was added HOBt
(399 mg, 2.95 mmol), NMM (0.81 mL, 7.38 mmol) and O-(tetrahydro-2H-pyran-2yl)hydroxylamine (432 mg, 3.69 mmol). After stirring for 1 h, EDC (660 mg, 3.44 mmol) was
added and the solution was stirred for 20 h at rt. The mixture was then partitioned between
EtOAc and water. The organic layer was washed with brine and dried over Na2SO4.

Chromatography on silica gel eluting with EtOAc/hexane provided the THP-protected
hydroxamate 18n as a yellow oil (940 mg, 70%). MS (CI) MH+ calcd for C28H34N2O2S, 559;
found, 559.

To a solution of THP-protected hydroxamate 18n (920 mg, 1.68 mmol) in 1,4-dioxane (15 mL)
was added 4N HCl in 1,4-dioxane (10 mL). After stirring at rt for 2 h the resulting precipitate
was collected by vacuum filtration and washed with diethyl ether to provide the Ncyclopropylpiperidine hydroxamate 19n as a white solid (510 mg, 60%). 1H NMR (400 MHz,
DMSO-d6) δ 11.18 (1H, br s), 9.34 (1H, br s), 7.70 (2H, d, J=9.0 Hz), 7.09 (2H, d, J=9.0 Hz),
6.96 (1H, d, J=8.6 Hz), 6.74 (1H, d, J=2.7 Hz), 6.66 (1H, dd, J=8.8, 2.9 Hz), 4.27 (4H, s), 3.60
(2H, d, J=11.7 Hz), 2.85-3.04 (3H, m), 2.53-2.59 (2H, m), 2.06-2.28 (2H, m), 0.91-1.03 (2H, m),
0.64-0.81 (2H, m). MS (CI) MH+ calcd for C23H26N2O7S, 475; found, 475. HRMS calcd for
C23H26N2O7S, 475.1539; found, 475.1553. Anal. calcd for C23H26N2O7S.1.15HCl.05H2O: C,
52.57; H, 5.40; N, 5.33; Cl, 7.76. Found: C, 52.62; H, 5.42; N, 5.79; Cl, 7.71.

1-cyclopropyl-N-hydroxy-4-(4-(4-(trifluoromethyl)phenoxy)phenylsulfonyl)piperidine-4carboxamide (19o). To a solution of the N-cyclopropyl piperidine ethyl ester p-fluoro sulfone
21o (5.96 g, 15.0 mmol) in DMF (100 mL) was added K2CO3 (12.34 g, 38.0 mmol) and α,α,αtrifluoromethylphenol (3.65 g, 22.5 mmol). The solution was stirred at 90°C for 28 h. The
solution was the cooled and diluted with H2O (400 mL) and extracted with EtOAc. This organic
phase was washed with water and brine and dried over MgSO4, filtered and concentrated in
vacuo to afford the desired aryl ether 20o (7.54 g, 100%) as an oil.

To the ethyl ester 20o (7.54 g, 15.0 mmol) in ethanol (40 mL) and THF (40 mL) was added a
solution of NaOH (6.06 g, 15.1 mmol) in water (20 mL) and the solution was heated at 60°C for
18 h. The reaction mixture was then concentrated in vacuo and the aqueous residue was
acidified to pH=2.0. The resulting precipitate was filtered to give carboxylic acid piperidine
hydrochloride salt 17o (7.98 g, 100%) as a white solid: HRMS MH+ calcd for C22H22NSO5F3,
470.1171; found, 470.1253

To a solution of the carboxylic acid 17o (7.60 g, 15.0 mmol) in DMF (100 mL) were added
HOBt (2.44 g, 18.0 mmol), NMM (3.4 mL, 30.9 mmol) and O-(tetrahydro-2H-pyran-2yl)hydroxylamine hydrochloride (2.63 g, 22.5 mmol) followed by EDC (4.02 g, 21.0 mmol).
The solution was stirred at rt for 96 h. The reaction was then diluted with H2O (400 mL) and
extracted with EtOAc. The organic layer was washed with brine and dried over MgSO4, filtered
and concentrated in vacuo. Chromatography on silica gel eluting with EtOAc/hexane (30/70)
provided the THP-protected hydroxamate 18o (5.93 g, 69%) as a white solid.

To a solution of the THP-protected hydroxamate 18o (3.8 g, 6.7 mmol) in 1,4-dioxane (100 mL)
was added 4N HCl in 1,4-dioxane (30 mL). The reaction was stirred at rt for 2 h, then the
solution was concentrated in vacuo. Trituration of the residue with diethyl ether afforded the Ncyclopropyl piperidine hydroxamate hydrochloride salt (3.33 g, 96%) as a white solid: DSC
207.29-211.84°C at 373.8 J/g. 1H NMR (400 MHz, DMSO-d6) δ 9.69 (1H, br s), 9.32 (1H, s),
7.75 (2H, d, J = 8 Hz), 7.49 (2H, d, J = 8 Hz), 7.32 (2H, d, J = 8 Hz), 7.19 (2H, d, J = 8 Hz), 3.60
(2H, m), 3.31 (2H, m), 2.95 (4H, m), 2.22 (1H, m), 0.99 (2H, m), 0.77 (2H, m). MS MH+ calcd
for C22H23N2SO5F3, 485; found, 485.

N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide
(19p). To a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (1.5 g, 3.61 mmol) in
DMF (10 mL) was added Cs2CO3 (2.95 g, 9.03 mmol) and α,α,α-trifluoro-p-cresol (877 mg,
5.41 mmol). The solution was heated to 90°C for 20 h. The solution was then cooled and
partitioned between EtOAc and water, and the organic layer was washed with brine and dried
over Na2SO4. Filtration through a pad of silica gel eluting with EtOAc provided diaryl ether 16p
as a yellow oil (2.30 g, 100%). MS(CI) MH+ calcd for C26H30NO7SF3, 558; found, 558.

To a solution of ethyl ester 16p (2.30 g, 3.61 mmol) in THF (10 mL) and ethanol (10 mL) was
added NaOH (1.44 g, 36.1 mmol) in water (5 mL) and the solution was heated to 60°C for 18 h.
The solution was concentrated and the aqueous residue was acidified to pH=2 with 10% aqueous
HCl and then extracted with EtOAc. The organic layer was washed with brine and dried over
Na2SO4. Concentration in vacuo provided the carboxylic acid 17p as a solid (2.11 g, 100%).
MS (CI) MH+ calcd for C24H26NO7SF3, 530; found, 530.

To a solution of carboxylic acid 17p (2.11 g, 3.61 mmol) in DMF (10 mL) was added HOBt (586
mg, 4.33 mmol), NMM (1.19 mL, 10.8 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine
(634 mg, 5.41 mmol). After stirring for 1h at rt, EDC (969 mg, 5.05 mmol) was added and the
solution was stirred for 18 h. The mixture was then partitioned between EtOAc and water. The
aqueous layer was extracted with EtOAc and the combined organic layers were washed with
water and brine and dried over MgSO4. Chromatography on silica gel eluting with

EtOAc/hexane provided the THP-protected hydroxamate 18p as a clear, colorless oil (1.40 g,
62%). MS (CI) MH+ calcd for C29H35N2O8SF3, 629; found, 629.

To a solution of the THP-protected hydroxamate 18p (1.40 g, 2.23 mmol) in 1,4-dioxane (10
nM) was added 4N HCl in 1,4-dioxane (15 mL) and the solution was stirred for 2h. The solution
was then diluted with diethyl ether and the resulting precipitate was collected by vacuum
filtration to provide compound 19p as a white solid (747 mg, 70%). 1H NMR (400 MHz,
DMSO-d6) δ 11.17 (1H, br s), 9.32 (1H, s), 8.78 (1H, d, J=8.99 Hz), 7.86 (2H, d, J=8.6 Hz), 7.78
(2H, d, J=8.99 Hz), 7.36 (2H, d, J=8.6 Hz), 7.29 (2H, d, J=8.99 Hz), 3.40 (2H, d, J=12.5 Hz),
2.58-2.70 (2H, m), 2.42-2.58 (2H, m), 2.04-2.20 (2H, m). MS (CI) MH+ calcd for
C19H19N2O5SF3, 445; found, 445. HRMS calcd for C19H19N2O5SF3, 445.1045; found, 445.1052.
Anal. calcd for C19H19N2O5SF3.0.5H20.1.0HCl: C, 46.58; H, 4.32; N, 5.72; S, 6.55; Cl, 7.24.
Found: C, 46.58; H, 3.82; N, 5.61; S, 6.96; Cl, 7.37.

N-hydroxy-1-(2-morpholin-4-ylethyl)-4-({4-[4(trifluoromethyl)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide (19q). According to
the general procedure specified for hydroxamate 19m, N-morpholinylethyl piperidine
hydroxamate 19q was prepared as a colorless foam. 1H NMR (400 MHz, DMSO-d6) δ 11.22
(1H, br s), 7.73-7.90 (4H, m), 7.40 (2H, d, J=8.5 Hz), 7.30 (2H, d, J=8.9 Hz), 3.22-4.08 (8H, m),
2.94-3.23 (2H, m), 2.45-2.89 (6H, m), 2.32 (2H, d, J=12.3 Hz), 1.67-2.05 (2H, m). HRMS MH+
calcd for C25H30F3N3O6S, 558.1886; found, 558.1894.

N-hydroxy-4-{[4-(4-isopropoxyphenoxy)phenyl]sulfonyl}tetrahydro-2H-pyran-4carboxamide (19r). To a solution of N-BOC piperidine 1542 (30.0 g, 80.8 mmol) in methylene
chloride (100 mL) was added trifluoroacetic acid (30 mL) in methylene chloride (40 mL). The
solution was stirred at rt for 2 h and then concentrated in vacuo. To the residue redissolved in
methylene chloride (150 mL) at 0°C were added triethylamine (28.0 mL, 277 mmol), acetone
(24.0 mL, 413 mmol), sodium cyanoborohydride (68 g, 323.1 mmol) and acetic acid (18.5 mL,
308 mmol). The reaction mixture was stirred at rt for 18 h, then diluted with 1N NaOH and
extracted with ethyl ether. The organic layer was washed with 1n NaOH, water, brine and dried
over MgSO4, filtered and concentrated in vacuo to provide the desired N-isopropyl piperidine
22r (21.03 g, 72%).

To a solution of the N-isopropyl piperidine 22r (4.04 g, 11.0 mmol) in DMF (50 mL) was added
Cs2CO3 (10.75 g, 33.3 mmol) and α,α,α-trifluoro-p-cresol (2.67 g, 16.5 mmol). The solution
was stirred at 90°C for 40 h. The mixture was then diluted with H2O (400 mL) and extracted
with EtOAc. The organic layer was washed with water, brine and dried over MgSO4, filtered
and concentrated in vacuo. Chromatography on silica gel eluting with EtOAc/hexane (30/70)
provided diaryl ether 20r as an oil (5.35 g, 97%). 1H NMR (400 MHz, CDCl3) δ 7.77 (2H, d, J =
8 Hz), 7.68 (2H, d, J = 8 Hz), 7.17 (2H, d, J = 8 Hz), 7.10 (2H, d, J = 8 Hz), 4.23 (2H, q, J = 7
Hz), 2.92 (2H, m), 2.68 (1H, m), 2.37 (2H, m), 2.14 (2H, m), 2.06 (2H, m), 1.28 (3H, t, J = 7
Hz), 0.99 (6H, d, J = 7 Hz). HRMS MH+ calcd for C24H28NSO5F3, 500.1640; found, 500.1678.

To a solution of the ethyl ester 20r (5.3 g, 10.6 mmol) in ethanol (50 mL) and THF (50 mL) was
added a solution of NaOH (4.2 g, 106 mmol) in H2O (25 mL) and the solution was heated at

60°C for 18 h. The mixture was then concentrated in vacuo and the aqueous residue was
acidified to pH=3.0 with concentrated aqueous HCl. The resulting precipitate was filtered to
give the carboxylic acid as the piperidine hydrochloride salt 17r (5.38 g, 100%) as a white solid:
DSC 189.24-205.07°C at 115.7 J/g. HRMS MH+ calcd for C22H24NSO5F3, 472.1406; found,
472.1407.

To a solution of the carboxylic acid 17r (5.4 g, 10.6 mmol) in DMF (90 mL) were added HOBt
(1.72 g, 12.3 mmol), NMM (3.5 mL, 32.0 mmol) and O-tetrahydropyranyl hydroxylamine
hydrochloride (1.87 g, 15.9 mmol) followed by EDC (2.8 g, 15.0 mmol). The reaction was
stirred at rt for 144 h. The solution was then diluted with H2O (400 mL) and extracted with
EtOAc. The organic layer was washed with brine and dried over MgSO4, filtered and
concentrated in vacuo. Chromatography on silica gel eluting with methanol/EtOAc (2/98)
provided the THP-protected hydroxamate 18r (2.75 g, 45%) as a white solid: 1H NMR (400
MHz, CDCl3) δ 9.35 (1H, br s), 7.83 (2H, d, J = 8 Hz), 7.67 (2H, d, J = 8 Hz), 7.18 (2H, d, J = 8
Hz), 7.09 (2H, d, J = 8 Hz), 5.00 (1H, t, J = 1 Hz), 4.00 (1H, td, J = 7, 1Hz), 4.69 (1H, dt, J = 7, 1
Hz), 3.88 (2H, m), 2.69 (1H, m), 2.28 (2H, m), 2.20 (4H, m), 1.87 (2H, m), 1.80 (2H, m), 1.61
(2H, m), 0.99 (6H, d). HRMS MH+ calcd for C27H33N2SO5F3, 571.2090; found, 571.2103.

To a solution of the THP-protected hydroxamate 18r (2.7 g, 4.7 mmol) in 1,4-dioxane (50 mL)
was added 4N HCl in 1,4-dioxane (20 mL). The reaction was stirred at rt for 2 h. Filtration
afforded the hydroxamate as the piperidine hydrochloride salt 19r (2.08 g, 84%) as a white solid:
1

H NMR (400 MHz, DMSO-d6) δ 9.59 (1H, br s), 9.29 (1H, s), 7.84 (2H, d, J = 8 Hz), 7.78 (2H,

d, J = 8 Hz), 7.37 (2H, d, J = 8 Hz), 7.29 (2H, d, J = 8 Hz), 3.57 (1H, m), 3.41 (1H, m), 2.60 (4H,
m), 2.26 (1H, m), 1.21 (6H, d, J = 7 Hz). MS MH+ calcd for C22H25SN2O5F3, 487; found, 487.

1-ethyl-N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)piperidine-4carboxamide (19s). Through a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (48 g,
115 mmol) in EtOAc (750 mL) at 0°C was bubbled HCl gas for 45 min, then stirred at 0°C for 7
h. The solution was concentrated in vacuo to afford a residue that was triturated with diethyl
ether to afford piperidine hydrochloride salt 21 (32.76 g, 81%) as a white solid.

To a solution of the piperidine hydrochloride salt 21 (15.8 g, 45.0 mmol) in DMF (75 mL) was
added K2CO3 (12.4 g, 90.0 mmol) and bromoethane (3.4 mL, 45.0 mmol). The solution was
stirred at rt for 18 h, then diluted with H2O (200 mL) and extracted with EtOAc. The organic
layer was washed with H2O, brine and dried over MgSO4, filtered and concentrated in vacuo to
provide the desired N-ethyl piperidine 22s (15.4 g, 100%) as an oil. 1H NMR (400 MHz, CDCl3)
δ 7.80 (2H, m), 7.22 (2H, m), 4.19 (2H, t, J = 7 Hz), 2.98 (2H, m), 2.33 (5H, m), 2.17 (1H, td, J =
11, 1 Hz), 1.82 (1H, td, J = 11, 1Hz), 1.24 (3H, t, J = 7 Hz), 1.03 (3H, t, J = 7 Hz). HRMS calcd
for C16H22NSO4F, 343.1254; found, 343.1292.

To a solution of the N-ethyl piperidine p-fluoro sulfone 22s (5.2 g, 15.0 mmol) in DMF (50 mL)
was added Cs2CO3 (12.2 g, 37.5 mmol) and α,α,α,-trifluoro-p-cresol (3.65 g, 23.0 mmol). The
solution was stirred at 90°C for 25 h. The reaction mixture was then diluted with H2O (400 mL)
and extracted with EtOAc. The organic layer was washed with water, brine and dried over
MgSO4, filtered and concentrated in vacuo. Chromatography on silica gel eluting with

EtOAc/hexane (20/80) provided the diaryl ether 20s (7.3 g, 100%) as an oil. 1H NMR (400
MHz, CDCl3) δ 7.78 (2H, d, J = 8 Hz), 7.68 (2H, d, J = 8 Hz), 7.17 (2H, d, J = 8 Hz), 7.10 (2H,
d, J = 8 Hz), 4.21 (2H, t J = 7 Hz), 2.99 (2H, m), 2.34 (6H, m), 2.17 (2H, td, J = 11, 5 Hz), 1.83
(2H, td, J = 11, 1 Hz), 1.27 (3H, t, J = 7 Hz), 1.05 (3H, t, J = 7 Hz). MS MH+ calcd for
C23H26NSO5F3, 486; found, 486.

To a solution of the ethyl ester 20s (7.3 g, 15.0 mmol) in ethanol (40 mL) and THF (40 mL) was
added a solution of NaOH (6.0 g, 150 mmol) in water (30 mL) and the solution was heated at
60°C for 16 h. The solution was then concentrated in vacuo and the aqueous residue was
acidified to pH = 4.0. The resulting precipitate was filtered to give carboxylic acid piperidine
hydrochloride salt 17s (5.96 g, 80%) as a white solid: DSC 177.57-189.45°C at 117.2 J/g.
HRMS MH+ calcd for C21H22NSO5F3, 458.1249; found, 458.1260.

To a solution of the hydrochloride salt 17s (5.96 g, 12.0 mmol) in DMF (80 mL) were added
HOBt (1.96 g, 14.0 mmol), NMM (3.9 mL, 36.0 mmol) and O-(tetrahydro-2H-pyran-2yl)hydroxylamine (2.11 g, 18.0 mmol) followed by EDC (3.24 g, 17.0 mmol). The reaction was
stirred at rt for 18 h. The insoluble material was removed by filtration and the filtrate was
diluted with H2O (400 mL) and extracted with EtOAc. The organic layer was washed with brine
and dried over MgSO4, filtered and concentrated in vacuo. Chromatography on silica gel eluting
with EtOAc/hexane (70/30) provided the THP-protected hydroxamate 18s (2.80 g, 41%) as a
white solid. MS MH+ calcd for C28H39N2SO6, 531; found, 531.

To a solution of the THP-protected hydroxamate 18s (2.8 g, 5.0 mmol) in 1,4-dioxane (80 mL)
was added 4N HCl in 1,4-dioxane (20 mL). The reaction was stirred at rt for 5 h and then
concentrated in vacuo. Trituration with diethyl ether afforded the hydroxamate piperidine
hydrochloride salt (2.08 g, 84%) as a white solid: DSC 229.31-235.74°C at 187.8 J/g. 1H NMR
(400 MHz, DMSO-d6) δ 9.32 (1H, s), 7.83 (2H, d, J = 8 Hz), 7.78 (2H, d, J = 8 Hz), 7.37 (2H, d,
J = 8 Hz), 7.29 (2H, d, J = 8 Hz), 3.57 (2H, m), 3.05 (2H, m), 2.60 (2H, m), 2.54 (2H, m), 2.23
(2H, m), 1.18 (3H, t, J = 7 Hz). HRMS MH+ calcd for C21H23N2SO5F3, 473.1358; found,
473.1361. Anal calcd for C21H23N2SO5F3.HCl: C, 49.56; H, 4.75; N, 5.50; Cl, 6.70; S, 6.30.
Found: C, 49.18; H, 4.61; N, 5.51; Cl, 6.95; S, 6.14.

N-hydroxy-1-(2-methoxyethyl)-4-[(4-{4[(trifluoromethyl)thio]phenoxy}phenyl)sulfonyl]piperidine-4-carboxamide (19t). To a
solution of N-methoxyethyl-piperidine p-flourosulfone 22t (5.0 g, 13.4 mmol) and powdered
K2CO3 (3.7 g, 27 mmol) in DMF (20 mL) was added 4-(trifluoromethylthio)phenol (3.9 g, 20
mmol) and the mixture was heated to 90°C for 24h. The solution was concentrated under high
vacuum and the residue was dissolved in EtOAc. The organic phase was washed with 1N
aqueous NaOH, water, and dried over MgSO4. Chromatography on silica gel eluting with
EtOAc/hexane provided diaryl ether 20t as a light yellow gel (5.94 g, 81.0%).

To a solution of the ethyl ester 20t (5.94 g, 210 mmol) in ethanol (10 mL) and THF (10 mL) was
added a solution of NaOH (4.34 g, 108 mmol) in water (20 mL). The solution was then heated to
60°C for 24 h. After cooling the solution was concentrated in vacuo and diluted with water.

This aqueous phase was washed with diethyl ether and then acidified to pH=2. Vacuum filtration
of the resulting precipitate provided the carboxylic acid 17t (5.5 g, 100%) as a white solid.

To a solution of the carboxylic acid 17t (5.5 g, 10.8 mmol), NMM (3.6 mL, 32.4 mmol) HOBt
(4.4 g, 32.4 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (2.6 g, 21.8 mmol) in DMF
(200 mL) was added EDC (6.2 g, 32.4 mmol) and the solution was stirred at rt for 24 h. The
reaction mixture was then concentrated under high vacuum and the residue dissolved in EtOAc.
This organic phase was washed with saturated aqueous NaHCO3, water, and dried over MgSO4.
Concentration in vacuo and chromatography on silica gel eluting with EtOAc/hexane provided
the THP-protected hydroxamate 18t (4.66 g, 69.8%) as a white foam.

To a solution of the THP-protected hydroxamate 18t (4.65 g, 7.9 mmol) in methanol (2.5 mL)
and 1,4-dioxane (8 mL) was added a 4N solution of HCl in 1,4-dioxane (20 mL, 79 mmol) and
the solution was stirred at rt for 3h. Concentration in vacuo gave a residue which was triturated
with diethyl ether to afford the N-methoxyethyl piperidine hydroxamate (3.95 g, 92.1%) as a
white solid: 1H NMR (400 MHz, DMSO-d6) δ 11.21 (1H, s), 10.50 (1H, br s), 9.37 (1H, br s),
7.81 (4H, d, J=8.5 Hz), 7.32 (4H, dd, J=16.9, 8.7 Hz), 3.53-3.74 (4H, m), 3.20-3.30 (5H, m),
2.70-2.87 (2H, m), 2.46-2.59 (2H, m), 2.30 (2H, t, J=12.1 Hz). HRMS calcd for
C22H25F3N2O6S2, 535.1184; found, 535.1179. Anal calcd for C22H25F3N2O6S2.HCl: C, 46.27; H,
4.59; N, 4.91; S, 11.23. Found: C, 46.02; H, 4.68; N, 4.57; S, 11.11.

N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide
(19u). To a solution of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (1.5 g, 3.61 mmol) in

DMF (10 mL) was added Cs2CO3 (2.94 g, 9.03 mmol) and 4-(trifluoromethoxy)phenol (0.70 mL,
5.41 mmol). The solution was heated to 90°C for 20 h. The solution was then cooled and
partitioned between EtOAc and water, and the organic layer was washed with brine and dried
over Na2SO4. Filtration through a pad of silica gel eluting with EtOAc provided the diaryl ether
16u as a yellow oil (2.11 g, 100%). MS(CI) MNa+ calcd for C26H30F3NO8S, 596, found 596.

To a solution of the ethyl ester 16u (2.11 g, 3.61 mmol) in THF (10 mL) and ethanol (10 mL)
was added a solution of sodium hydroxide (1.44 g, 36.1 mmol) in water (5 mL) and the solution
was heated to 60°C for 18h. The solution was concentrated and the aqueous residue was then
acidified to pH=2 with 10% aqueous HCl and extracted with EtOAc. The organic layer was
washed with brine and dried over Na2SO4. Concentration in vacuo provided the carboxylic acid
17u as a solid (2.2 g, 100%). MS(CI) MH+ calcd for C24H26NO8SF3, 546; found, 546.

To a solution of the carboxylic acid 17u (2.2 g, 3.6 mmol) in DMF (10 mL) was added HOBt
(586 mg, 4.33 mmol), NMM (1.19 mL, 10.8 mmol) and O-(tetrahydro-2H-pyran-2yl)hydroxylamine (634 mg, 5.41 mmol). After stirring at rt for 30 min, EDC (969 mg, 5.05
mmol) was added and the solution was stirred for 96 h. The solution was then partitioned
between EtOAc and water. The aqueous layer was extracted with EtOAc and the combined
organic layers were washed with water and brine and dried over MgSO4. Chromatography on
silica gel eluting with EtOAc/hexane provided the THP-protected hydroxamate 18u as a clear,
colorless oil (1.26 g, 53%).

To a solution of the THP-protected hydroxamate 18u (1.26 g, 1.96 mmol) in 1,4-dioxane (10
mL) was added 4N HCl in 1,4-dioxane (10 mL) and the solution was stirred for 2 h. The
solution was then diluted with ethyl ether and the resulting precipitate was collected by vacuum
filtration to provide 19u as a white solid (455 mg, 47%). 1H NMR (400 MHz, DMSO-d6) δ
11.16 (1H br s), 9.31 (1H, s), 8.79 (1H, d, J=8.99 Hz), 7.75 (2H, d, J=8.6 Hz), 7.51 (2H, d, J=8.6
Hz), 7.31 (2H, d, J=8.99 Hz), 7.20 (2H, d, J=8.99 Hz), 3.34-3.45 (2H, m), 2.57-2.70 (2H, m),
2.45 (2H, d, J=13.6 Hz), 2.10 (2H, t, J=12.5 Hz). MS(CI) MH+ calcd for C19H19N2O6SF3, 461;
found, 461. HRMS calcd for C19H19N2O6SF3, 461.0994; found, 461.0997. Anal calcd for
C19H19N2O6SF3.HCl: C, 45.93; H, 4.06; N, 5.64; S, 6.45; Cl, 6.45. Found: C, 46.23; H, 4.07; N,
5.66; S, 6.59; Cl, 7.03.

N-hydroxy-1-(2-methoxyethyl)-4-({4-[4(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide (19v). To a solution
of N-BOC 4-fluorophenylsulfone ethyl ester 1542 (30.0 g, 161 mmol) in dichloromethane (50
mL) cooled to 0°C was added trifluoroacetic acid (25 mL) and the solution was stirred at rt for 1
h. Concentration in vacuo provided the piperidine trifluoroacetate salt as a light yellow gel. To
the solution of the trifluoroacetate salt in DMF (50 ML) at 0°C was added K2CO3 (3.6 g, 26
mmol) and 2-bromoethyl methyl ether (19 mL, 201 mmol) and the reaction was stirred at rt for
36 h. The DMF was then removed under high vacuum and the residue was diluted with EtOAc.
This organic phase was washed with water and brine and dried over MgSO4. Concentration in
vacuo provided the N-methoxyethyl-piperidine 22v as a light yellow gel (26.03 g, 86.8%).

To a solution of the N-methoxyethyl piperidine 4-fluorosulfone 22v (6.0 g, 16.0 mmol) and
powdered K2CO3 (4.44 g, 32 mmol) in DMF (30 mL) was added 4-(trifluoromethoxy)phenol
(5.72 g, 32 mmol) and the mixture was then heated to 90°C for 25 h. The solution was
concentrated under high vacuum and the residue was dissolved in EtOAc. This organic phase
was washed with 1N aqueous NaOH, water, brine and dried over MgSO4. Chromatography on
silica gel eluting with EtOAc/hexane provided the trifluoromethoxy phenoxyphenyl sulfone 20v
as a light yellow gel (7.81 g, 91.5%).

To a solution of the ethyl ester 20v (7.81 g, 14.7 mmol) in ethanol (14 mL) and THF (14 mL)
was added a solution of NaOH (5.88 g, 147 mmol) in H2O (28 mL). The solution was then
heated to 60°C for 18h. The mixture was then concentrated in vacuo and diluted with water.
This aqueous phase was washed with ether and then acidified to pH=2 with concentrated
aqueous HCl. Vacuum filtration of the resulting precipitate provided carboxylic acid 16v (5.64
g, 73.3%) as a white solid.

To a solution of carboxylic acid 17v (5.64 g, 10.8 mmol), NMM (4.8 mL, 43.1 mmol), HOBt
(4.38 g, 32.4 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (2.5 g, 21.6 mmol) in
DMF (50 mL) was added EDC (6.2 g, 32.4 mmol) and the solution was stirred at rt for 24 h. The
reaction mixture was then concentrated under high vacuum and the residue was dissolved in
EtOAc. This organic phase was washed with saturated aqueous NaHCO3 and water and dried
over MgSO4. Concentration in vacuo and chromatography on silica gel eluting with
EtOAc/hexane provided the THP-protected hydroxamate 18v as a white foam (6.65 g, 100%).

To a solution of the THP-protected hydroxamate 18v (6.65 g, 11.03 mmol) in methanol (3 mL)
and 1,4-dioxane (9 mL) was added a 4N solution of HCl in 1,4-dioxane (28 mL, 110 mmol) and
the solution was stirred at rt for 3h. Concentration in vacuo and trituration with ether provided
the N-methoxyethyl piperidine hydroxamate hydrochloride salt 19v (4.79 g, 78.2%) as a white
solid: 1H NMR (400 MHz, DMSO-d6) δ 11.20 (1H, br s), 9.33 (1H, br s), 7.77 (2H, d, J=8.6
Hz), 7.51 (2H, d, J=8.99 Hz), 7.32 (2H, d, J=9.4 Hz), 7.21 (2H, d, J=8.99 Hz), 3.55-3.66 (4H,
m), 3.23-3.31 (5H, m), 2.71-2.85 (2H, m), 2.52-2.59 (2H, m), 2.18-2.30 (2H, m). HRMS MH+
calcd for C22H25F3N2O7S, 519.1413; found, 519.1399. Anal. calcd for
C22H25F3N2O7S.HCl.0.5H2O: C, 46.85; H, 4.83; N, 4.97; S, 5.69. Found: C, 46.73; H, 4.57; N,
4.82; S, 5.77.

1-Cyclopropyl-N-hydroxy-4-(4-(4-(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4carboxamide(19w). To a solution of the N-cyclopropyl amine p-fluoro sulfone 22w (6.97 g,
19.6 mmol) in DMF (500 mL) was added K2CO3 (3.42 g, 18.0 mmol) and 4-(trifluoromethoxy)phenol (3.7 g, 24.8 mmol). The solution was stirred at 90°C for 40 h. The mixture was then
diluted with H2O (600 mL) and extracted with EtOAc. The organic layer was washed with
water, brine and dried over MgSO4, filtered and concentrated in vacuo to afford the desired
diaryl ether 20w as an oil (8.5 g, 100%). HRMS MH+ calcd for C24H26NSO6F3, 514.1511;
found, 514.1524.

To a solution of the ethyl ester 20w (8.4 g, 16.4 mmol) in ethanol (50 mL) and THF (50 mL) was
added a solution of NaOH (6.54 g, 164 mmol) in H2O (20 mL) and the solution was heated to
60°C for 18 h. The solution was concentrated in vacuo to remove most of the organic solvents,

and the aqueous residue was acidified to pH=4.0. The resulting precipitate was filtered to give
carboxylic acid piperidine hydrochloride salt 17w (5.01 g, 63%) as a white solid: HRMS MH+
calcd for C22H22NSO6F3, 486.1198; found, 486.1200.

To a solution of the carboxylic acid 17w (5.0 g, 10.3 mmol) in DMF (80 mL) were added HOBt
(3.4 mL, 30.9 mmol) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (1.8 g, 15.4 mmol)
followed by EDC (1.60 g, 12.3 mmol). The solution was stirred at rt for 42 h. The reaction
mixture was then diluted with H2O (400 mL) and extracted with EtOAc. The organic layer was
washed with brine and dried over MgSO4, filtered and concentrated in vacuo. Chromatography
on silica gel eluting with EtOAc/hexane (30/70) provided the desired THP-protected
hydroxamate 18w (5.41 g, 89%) as a white solid. HPLC purity 98.38%.

To a solution of the THP-protected hydroxamate 18w (5.4 g, 9.2 mmol) in 1,4-dioxane (80 mL)
and methanol (20 mL) was added 4N HCl in 1,4-dioxane (50 mL). The reaction was stirred at rt
for 2.5 h, then the solution was concentrated in vacuo. Trituration with diethyl ether afforded the
N-cyclopropyl-piperidine hydroxamate 19w (4.02 g, 81%) as a white solid: DSC 224.98231.59°C at 392.0 J/g. 1H NMR (400 MHz, DMSO-d6) δ 9.58 (1H, br s), 9.34 (1H, s), 7.84 (2H,
d, J = 8.0 Hz), 7.77 (2H, d, J = 7.1 Hz), 7.37 (2H, d, J = 7.1 Hz), 7.28 (2H, d, J = 8.0 Hz), 3.60
(2H, m), 3.27 (2H, m), 2.95 (4H, m), 2.22 (1H, m), 0.97 (2H, m), 0.77 (2H, m). HRMS MH+
calcd for C22H23N2SO6F3, 501.1307; found, 501.1324. Anal. calcd for C22H23N2SO6F3.HCl: C,
49.30; H, 4.33; N, 5.23; Cl, 6.62; S, 5.98. Found: C, 49.13; H, 4.56; N, 5.17; Cl, 6.98; S, 6.24.

N-Hydroxy-1-(2-5 pyridinylmethyl)-4-[4-(4-trifluoro-methoxyphenoxy)phenyl]sulfonyl]-4piperidinecarboxamide, Dihydrochloride (19x). To a solution of 4-fluorophenylsulfone 1542
(6.22 g, 15 mmol) in DMF (7 mL) was added powdered K2CO3 (3.04 g, 22 mmol) and 4(trifluoromethoxy)phenol (3.92 g, 322 mmol) and the mixture was stirred at 90°C for 16 h.
Additional 4-(trifluoromethoxy)-phenol (1 g) and K2CO3 (800 mg) were added and the reaction
was continued at 115°C for 20 additional hours. The mixture was diluted with water (100 mL)
and extracted with EtOAc (100 mL, then 2×25 mL). The combined organic layers were dried
using MgSO4, concentrated, and chromatographed, affording the desired diaryl ether 16x as an
oil (9.6 g, 100%).
The N-BOC piperidine 16x (9.6 g, 15 mmol) was dissolved in EtOAc (45 mL). A solution of 4N
HCl in dioxane (12 mL, 48 mmol) was added, and the mixture was stirred at rt for 3 h.
Concentrated aqueous HCl (4 mL) was added and the reaction was heated to reflux with a heat
gun several times. The solution was concentrated and was then azeotroped with acetonitrile to
afford the piperidine hydrochloride salt as a foam (9.6 g). The piperidine hydrochloride salt (6.0
g) was dissolved in EtOAc (125 mL) and washed with aqueous sodium hydroxide (2 g NaOH in
50 mL water). The organic layer was dried with MgSO4 and filtered through a pad of silica gel.
The 4-(trifluoromethoxy)phenol contaminant was eluted, then the desired piperidine was freed
from the filter cake by elution with methanol containing 1% aqueous ammonium hydroxide (100
mL). The filtrate was concentrated and azeotroped with acetonitrile to yield the salt (3.3 g 7.3
mmol). This piperidine (1.24 g, 2.7 mmol) was combined with powdered K2CO3 (828 mg, 6.0
mmol), 2-picolyl hydrochloride (492 mg, 3.0 mmol), and DMF (3 mL), and the mixture was
stirred at ambient temperature for 2 h, then heated at 50°C for an additional 2 h. The mixture was
diluted with water (40 mL) and extracted with EtOAc (150 mL, then 50 mL). The combined

organic layers were dried using MgSO4, concentrated and chromatographed to afford the Npicolyl piperidine 20x as an oil (1.13 g, 74%).
To the ethyl ester 20x (1.1 g, 2.0 mmol) in ethanol (6 mL) and water (2 mL) was added KOH
(0.90 g, 16 mmol). The mixture was brought to reflux and heated for 4.5 h. The solution was
then cooled to 0°C and acidified using concentrated aqueous HCl. The solvent was removed, and
the resulting solids were dried by azeotroping with acetonitrile to afford carboxylic acid
piperidine hydrochloride 17x.

Carboxylic acid 17x was stirred with NMM (about 0.5 mL), 1-hydroxybenzotriazole (0.405 g, 3
mmol), O-tetrahydropyranyl hydroxylamine (0.35 g, 3.0 mmol), and DMF(9 mL). After ten
minutes, EDC (0.57 g, 3.0 mmol) was added, and the mixture was stirred overnight. The reaction
was then diluted with half-saturated aqueous NaHCO3 (50 mL) and extracted with EtOAc (100
mL, then 25 mL). The combined organic layers were dried over MgSO4, concentrated, and
chromatographed (9:1 EtOAc: methanol) to afford the desired THP-protected hydroxamate 18x
as a yellow oil (1.20 g, 95%).
The THP-protected hydroxamate 18x (1.20 g, 1.90 mmol) was dissolved in methanol (9 mL).
Acetyl chloride (0.78 mL, 11 mmol) was added over two minutes. The reaction was stirred for 2
hours at ambient temperature, then concentrated to afford the hydroxamate as the
dihydrochloride salt 19x (1.20 g, 100%) as a white crystalline solid. 1H NMR (400 MHz,
DMSO-d6) δ 11.19 (1H, br s), 8.67 (1H, d, J=3.91 Hz), 7.92 (1H, td, J=7.6, 1.6 Hz), 7.77 (2H, d,
J=8.99 Hz), 7.43-7.56 (4H, m), 7.31 (2H, d, J=8.99 Hz), 7.20 (2H, d, J=8.99 Hz), 4.46 (2H, br s),
3.51 (2H, d, J=11.7 Hz), 2.83-2.98 (2H, m), 2.52-2.60 (2H, m), 2.30 (2H, d, J=16.4 Hz). HRMS

calcd for C25H24F3N3O6, 552.1416; found, 522.1428. Anal. calcd for C25H24F3N3O6S.2HCl.1/3
H2O: C, 47.58; H, 4.07; N, 6.66. Found: C, 47.31; H, 4.14; N, 6.80.

N-hydroxy-1-(pyridin-3-ylmethyl)-4-({4-[4(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide (19y). To a solution
of N-BOC ethyl ester trifluorophenoxy ether 16p (2.64 g, 4.6 mmol) in 1,4-dioxane (5 mL) was
added 4N HCl in 1,4-dioxane (5 mL) and the solution was stirred for 2 h at rt. The solution was
then diluted with ethyl ether and the resulting precipitate was collected by vacuum filtration to
provide the deprotected piperidine as the hydrochloride salt (2.4 g, 100%). To a solution of this
hydrochloride salt (2.4 g, 4.6 mmol) in DMF (12 mL) was added 3-picolyl chloride (1.5 g, 8.8
mmol) and K2CO3 (4.3 g, 31 mmol) and the mixture was heated to 50°C for 24 h under an
atmosphere of nitrogen. The reaction mixture was then concentrated in vacuo, dissolved in water
and extracted with EtOAc (3X). The combined organic layers were washed with water and brine
and dried over MgSO4 and then concentrated in vacuo. The residue was purified by
chromatography on silica gel eluting with EtOAc/hexane (50:50) to afford the 3-picolyl
piperidine 20y as an amber oil (1.6 g, 60%): MS MH+ calcd for C27H27N2O6SF3, 565; found,
565. Anal. calcd for C27H27N2O6SF3: C, 57.44; H, 4.82; N, 4.96; S, 5.68. Found: C, 57.49; H,
5.10; N, 4.69; S, 5.67.

To a solution of the 3-picolyl piperidine ethyl ester 20y (1.5 g, 2.6 mmol) in THF (22 mL)
ethanol (22 mL) and water (11 mL) was added a 50% aqueous NaOH solution (2.1 g, 26 mmol)
and the solution was heated to 65°C for 24 h. The mixture was concentrated in vacuo and
triturated with ether to afford a tan solid which was dissolved in water and acidified to pH = 1

with concentrated hydrochloric acid. The mixture was then concentrated in vacuo and dried at
45°C under vacuum to afford carboxylic acid 17y (2.5 g): MS MH+ calcd for C25H23N2O6SF3,
537; found, 537.

To a solution of carboxylic acid 17y (2.5 g) in DMF (40 mL) was added HOBt (1.0 g, 7.7 mmol),
NMM (0.64 g, 7.7 mmol), O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (0.60 g, 5.1 mmol) and
EDC (1.5 g, 7.7 mmol) and the reaction was stirred at rt for 5 d. The mixture was then
concentrated in vacuo, dissolved in EtOAc, washed with water and brine, and dried over MgSO4.
Concentration in vacuo gave a residue which was purified by chromatography on silica gel
eluting with methanol/chloroform (5/95) to afford the THP-protected hydroxamate 18y as a
colorless foam (1.1 g, 66%): MS MH+ calcd for C30H32N3O7SF3, 636; found, 636.

T a solution of the THP-protected hydroxamate 18y (1.0 g, 1.6 mmol) in methanol (11 mL) was
added acetyl chloride (0.34 mL, 4.7 mmol) and the solution was stirred at rt for 2.5 h and then
poured into diethyl ether. The resulting precipitate was then isolated by filtration and dried at
46°C in a vacuum oven to afford the N-picolyl hydroxamate 19y as a white solid (0.85 g, 87%).
1

H NMR (400 MHz, DMSO-d6) δ 11.14 - 11.33 (2H, br s), 8.88 (1H, s), 8.77 (1H, d, J=6.2 Hz),

8.32 (1H, d, J=8.2 Hz), 7.76 (2H, d, J=8.99 Hz), 7.69-7.74 (1H, m), 7.48 (2H, d, J=8.20 Hz),
7.33 (2H, d, J=8.99 Hz), 7.20 (2H, d, J=8.99 Hz), 4.39 (2H, br s), 3.43 (2H, d, J=12.1 Hz), 2.712.91 (2H, m), 2.51-2.58 (2H, m), 2.23-2.36 (2H, m). HRMS MH+ calcd for C25H24N3O6SF3
552.1416, found 552.1417. Anal. calcd for C25H24N3O6SF3.2.2HCl: C, 47.53; H, 4.18; N, 6.65;
S, 5.08. Found: C, 47.27; H, 4.34; N, 6.60; S, 5.29.

1-(2-ethoxyethyl)-N-hydroxy-4-({4-[4(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide (19z). To a solution
of N-BOC piperidine 15 (1.0 g, 2.4 mmol) in dichloromethane (10 mL) was added trifluoroacetic
acid (10 mL) and the solution was stirred at ambient temperature for 1 hour. Concentration in
vacuo provided the amine trifluoroacetate salt 21 as a light yellow gel. To the solution of the
amine trifluoroacetate salt in DMF (5 mL) was added K2CO3 (0.99 g, 7.2 mmol) and 2bromoethyl ethyl ether (0.33 mL, 2.87 mmol) and the solution was stirred at ambient temperature
for 36 hours. Then DMF was evaporated under high vacuum and the residue was diluted with
EtOAc. The organic layer was washed with water and dried over MgSO4. Concentration in vacuo
provided the ethoxyl ethyl piperidine 22z as a light yellow gel (0.68 g, 65.4%).

To a solution of 4-fluorophenylsulfone 22z (0.68 g, 1.56 mmol) and powdered K2CO3 (0.43 g,
3.1 mmol) in DMF (5 mL) was added 4-(trifluoromethoxy)phenol (0.4 mL, 3.08 mmol) and the
solution was heated to 90°C for 25 hours. The solution was concentrated under high vacuum and
the residue was dissolved in EtOAc. The organic layer was washed with 1N NaOH, water and
dried over MgSO4. Chromatography on silica eluting with EtOAc/hexane provided the desired
diaryl sulfone 20z as a light yellow gel (1.0 g, quantitative).

To a solution of ethyl ester 20z (1.0 g, 1.72 mmol) in ethanol (2 mL) and tetrahydrofuran (2 mL)
was added NaOH (0.688 g, 17.2 mmol) in water (4 mL). The solution was then heated to 60°C
for 18 hours. The solution was concentrated in vacuo and diluted with water. The aqueous layer
was extracted with ether and acidified to pH=2. Vacuum filtration of the white precipitate
provided the carboxylic acid 17z as a white solid (0.94 g, 100%).

To a solution of carboxylic acid 17z (0.94 g, 1.86 mmol), NMM (0.61 mL, 5.55 mmol), HOBt
(0.76 g, 5.59 mmol) and O-tetrahydropyranyl hydroxyl amine (0.33 g, 2.7 mmol) in DMF (40
mL) was added EDC (1.06 g, 5.59 mmol) and the solution was stirred at rt for 24 h. The solution
was concentrated under high vacuum and the residue was dissolved in EtOAc. The organic layer
was washed with saturated aqueous NaHCO3, water and dried over MgSO4. Concentration in
vacuo and chromatography on silica eluting with EtOAc/hexane provided the THP-protected
hydroxamate 18z as a white foam (0.74 g, 66.1%).

To a solution of 4N hydrochloric acid (3 mL, 12 mmol)) in dioxane was added a solution of
THP-protected hydroxamate 18z (0.74 g, 1.2 mmol) in methanol (0.4 ml) and dioxane (1.2 mL)
and was stirred at rt for 3 h. Filtration of precipitation gave the title compound as white solid
(0.217 g, 32.9%). 1H NMR (400 MHz, DMSO-d6) δ 11.19 (1H, s), 9.33 (1H, br s), 7.77 (2H, d,
J=8.59 Hz), 7.50 (2H, d, J=8.2 Hz), 7.33 (2H, d, J=8.99 Hz), 7.21 (2H, d, J=8.99 Hz), 3.64-3.70
(2H, m), 3.59 (2H, d, J=12.1 Hz), 3.45 (2H, q, J=7.0 Hz), 3.19-3.28 (2H, m), 2.71-2.86 (2H, m),
2.52-2.57 (2H, m), 2.28 (2H, t, J=13.5 Hz), 1.12 (2H, t, J=7.0 Hz). HRMS MH+ calcd for
C23H27N2O7SF3, 533.1459; found, 533.1566. Anal. calcd for C23H27N2O7SF3.HCl.H2O: C,
47.06; H, 5.15; N, 4.77; S, 5.46. Found: C, 46.73; H, 4.57; N, 4.82; S, 5.77.

N-hydroxy-1-(2-hydroxyethyl)-4-({4-[4(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide (19aa). To a
solution of piperidine hydrochloride 21 (3.95 g, 11.3 mmol) in DMF (11 mL) was added K2CO3
(3.45 g, 25 mmol) and 2-(2-bromoethoxy)tetrahydro-2H-pyran (1.85 mL, 12 mmol) and the

mixture was stirred for 48 hours at rt. The reaction was diluted with water (100 mL) and
extracted with EtOAc (100 mL, then 50 mL). The combined organic layers were dried over
MgSO4, concentrated, and chromatographed to afford the desired tetrahydropyranyl ether 22aa
as an oil (4.44 g, 88%)

A solution of tetrahydropyranyl ether 22aa in DMF (5 mL) was stirred at 110°C for 20 hours in
the presence of powdered K2CO3 (2.07 g, 15 mmol) and 4-(trifluoromethoxy)phenol (2.67 mL,
15 mmol). The mixture was diluted with saturated NaHCO3 (50 mL) and was extracted with
EtOAc (150, then 50 mL). The combined organic layers were dried over MgSO4, concentrated,
and chromatographed to afford diaryl ether 20aa as an oil (5.72 g, 100%).

Ethyl ester 20aa (1.28 g, 2.1 mmol) was refluxed in the presence of KOH (954 mg, 16.8 mmol),
ethanol (9 mL), and water (3 mL). After 2 hours, the reaction was cooled to 0°C. Concentrated
hydrochloric acid was added drop-wise to adjust the pH to 4.0. The acidified reaction was
concentrated, azeotroped with acetonitrile, and dried in vacuo, affording carboxylic acid 16aa.

Carboxylic acid 17aa was converted to the O-THP hydroxamate using O-tetrahydropyranyl
hydroxylamine (351 mg, 3 mmol), NMM (0.5 mL), HOBt (405 mg, 3 mmol), and EDC (573 mg,
3 mmol) in DMF(9 mL) at rt for 16h. After an aqueous workup, the THP-protected hydroxamate
18aa (855 mg, 60%) was obtained as an oil.

The tetrahydropyranyl hydroxamate 18aa (855 mg, 1.26 mmol) was dissolved in methanol (10
mL). Acetyl chloride (0.78 mL, 11 mmol) was added over 2-3 minutes. After 4 hours both THP

groups had been cleaved. The reaction was concentrated, azeotroped with
chloroform/acetonitrile, and dried in vacuo affording hydroxamate 19aa as a white foam (676
mg, 98%). 1H NMR (400 MHz, DMSO-d6) δ 11.19 (1H, br s), 9.33 (1H, br s), 7.77 (2H, d,
J=8.99 Hz), 7.50 (2H, d, J=8.2 Hz), 7.33 (2H, d, J=8.99 Hz), 7.21 (2H, d, J=8.99 Hz), 5.29 (1H,
br s), 3.69 (2H, br s), 3.60 (2H, d, J=13.3 Hz), 3.13 (2H, br s), 2.78 (2H, d, J=11.7 Hz), 2.48-2.58
(2H, m), 2.21-2.39 (2H, m). HRMS MH+ calcd for C21H23F3N2O7S, 505.1256; found, 505.1250.

1-acetyl-N-hydroxy-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4carboxamide (19bb). To a solution of 4-fluorophenylsulfone 15 (33.2 g, 80.0 mmol) in DMF
(150 mL) was added Cs2CO3 (65.2 g, 200 mmol) and 4-(trifluoromethoxy)phenol (21.4 g, 120
mmol). The solution was mechanically stirred at 60°C for 24 hours. The solution was then
diluted with water (1 L) and extracted with EtOAc. The organic layer was washed with water,
brine and dried over MgSO4, then filtered and concentrated in vacuo. Chromatography on silica
gel eluting with 20% EtOAc/hexane provided the desired diaryl ether 16bb as a white solid (45.0
g, 100%).

To a solution of ethyl ester 16bb (24.0 g, 42.8 mmol) in ethanol (80 mL) and THF (80 mL) was
added a solution of NaOH (14.8 g, 370 mmol) in water (100 mL) and the solution was heated at
60°C for 18 hours. The solution was concentrated in vacuo and the aqueous residue was acidified
to pH=5.0 and extracted with EtOAc. The organic extract was washed with brine and dried over
MgSO4, then filtered and concentrated in vacuo to give the desired carboxylic acid 17bb as a
white foam (23.0 g, 100%).

Through a solution of carboxylic acid 17bb (22.8 g, 43.0 mmol) in EtOAc (400 mL) cooled to
0°C was bubbled gaseous HCl for 20 minutes. The reaction was stirred at this temperature for
2.5 hours. The solution was then concentrated in vacuo to afford the piperidine hydrochloride
salt as a white foam (21.0 g, 100%).

To a solution of hydrochloride salt (17, R = H) (17.0 g, 35.0 mmol) in acetone (125 mL) and
water (125 mL) was added triethyl amine (24 mL, 175 mmol). The reaction was cooled to 0°C
and acetyl chloride (3.73 mL, 53.0 mmol) was added. The solution was then stirred at ambient
temperature for 18 hours. Concentration in vacuo gave a residue which was acidified with
aqueous hydrochloric acid to pH 1.0 and then extracted with EtOAc. The organic layer was
washed with water, saturated aqueous sodium chloride and dried over MgSO4, then filtered and
concentrated in vacuo to give the desired acetamide 17bb as a white solid (17.0 g, quantitative
yield).

To a solution of the acetamide 17bb (14.4 g, 29.6 mmol) in DMF (250 mL) was added HOBt
(4.8 g, 35.5 mmol), NMM (12.3 mL, 88.8 mmol) and O-(tetrahydro-2H-pyran-2yl)hydroxylamine (5.2 g, 44.4 mmol) followed by EDC (7.99 g, 41.4 mmol). The solution was
stirred at ambient temperature for 18 hours. The solution was diluted with water (500 mL) and
extracted with EtOAc. The organic layer was washed with saturated aqueous sodium chloride
and dried over MgSO4, then filtered and concentrated in vacuo. Chromatography on a C-18
reverse-phase column eluting with acetonitrile/water provided the desired THP-protected
hydroxamate 18bb as a white solid (12.0 g, 71%).

To a solution of THP-protected hydroxamate 18bb (12.0 g, 20.5 mmol) in 1,4-dioxane (250 mL)
and methanol (50 mL) was added 4 N HCl/dioxane (51 mL). After stirring at rt for 3.5 hours the
solution was concentrated in vacuo. Trituration with diethyl ether and filtration provided
piperidine acetamide hydroxamate 19bb as a white solid (8.84 g, 85%). HRMS MH+ calcd for
C21H21N2SO7F3, 502.1021; found, 502.0979. Anal. calcd for C21H21N2SO7F3: C, 50.20; H, 4.21;
N, 5.58; S, 6.38. Found: C, 49.93; H, 4.14; N, 5.60; S, 6.56.

N-hydroxy-1-prop-2-yn-1-yl-4-({4-[4(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4-carboxamide (19cc). N-Propargyl
piperidine hydroxamate 19cc was prepared according to the procedure outlined for 19v. 1H
NMR (400 MHz, DMSO-d6) δ 11.17 (1H, br s), 9.37 (1H, br s), 7.77 (2H, d, J=8.99 Hz), 7.50
(2H, d, J=8.2 Hz), 7.33 (2H, d, J=8.99 Hz), 7.20 (2H, d, J=8.99 Hz), 4.08 (2H, br s), 3.82 (1H, br
s), 3.48-3.70 (2H, m), 2.79-2.80 (2H, m), 2.52-2.63 (2H, m), 2.14-2.32 (2H, m). HRMS MH+
calcd for C22H21F3N2O6S, 499.1151; found, 499.1145.

N-hydroxy-1-methyl-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4carboxamide (19dd). N-Methyl piperidine hydroxamate 19dd was prepared according to the
procedure outlined for 19v. 1H NMR (400 MHz, DMSO-d6) δ 11.18 (1H, s), 9.33 (1H, s), 7.77
(2H, d, J=8.99 Hz), 7.50 (2H, d, J=8.6 Hz), 7.33 (2H, d, J=9.4 Hz), 7.20 (2H, d, J=8.99 Hz), 3.48
(2H, d, J=13.7 Hz), 2.72-2.83 (2H, m), 2.70 (3H, br s), 2.51-2.58 (2H, m), 2.17-2.29 (2H, m).
HRMS MH+ calcd for C20H21F3N2O6S, 475.1151; found, 475.1142.

N-hydroxy-1-isopropyl-4-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfonyl)piperidine-4carboxamide (19ee). N-Isopropyl piperidine hydroxamate 19ee was prepared according to the
procedure outlined for 19v. HRMS MH+ calcd for C22H25F3N2O6S 503.1464, found 503.1461.
1H NMR (400 MHz, DMSO-d6) δ 9.31 (1H, s) 11.22 (1H, s), 7.77 (2H, d, J=8.99 Hz), 7.49 (2H,
d, J=8.2 Hz), 7.34 (2H, d, J=8.99 Hz), 7.22 (2H, d, J=8.99 Hz), 3.65-3.75 (1H, m), 3.54 (2H, d,
J=10.9 Hz), 3.37-3.46 (2H, m), 2.52-2.66 (2H, m), 2.20-2.35 (2H, m), 1.21 (3H, s), 1.20 (3H, s).

Crystallography

Crystals of the MMP13:tetrahydro-N-hydroxy-4-[[4-(phenylmethyl)-1-piperazinyl]sulfonyl]-2Hpyran-4-carboxamide, hydrochloride66 complex were grown at 4°C by sitting drop vapor
diffusion using 5 mg/mL protein and a reservoir solution of 1.4M lithium sulfate, 0.1M Hepes,
pH 7.7. The crystallization drop consisted of 5µL protein plus 1µL reservoir solution. Rod-like
crystals appeared within four to six weeks. Crystals were pre-equilibrated in a soaking solution
containing 1.5M lithium sulfate, 0.1M Hepes, pH 7.7 without inhibitor at room temperature for
more than two hours. These crystals were then transferred to a second solution containing 1.5M
lithium sulfate, 0.1M Hepes, pH 7.7 and 2.5mM of replacement inhibitor (19v) and were left to
incubate at room temperature for five to seven days. The cryo solution consisted of 20%
sucrose, 1.5M lithium sulfate, and 0.1M Hepes, pH 7.7. Data were collected using a Rigaku
Micromax 007 X-ray generator on a Mar Research MarCCD 165 detector. The diffraction data
were integrated and scaled with HKL-200067, and the structures were determined by molecular
replacement using a prior internal structure of MMP-13 as the initial model.

The model

adjustment occurred as in Kjeldgaard68 and Coot69, and the structures were refined (Table 4)
initially with X-PLOR70 and were further optimized in Refmac71.

Table 4. Crystallographic data and refinement statistics
PDB accession code

3KRY

Data collection statistics
Radiation source

Rotating anode

Radiation detector

MAR CCD 165

Space group
Resolution (Å)

P1
20.0-1.9 (1.97-1.90)

Observed reflections

84,869

Unique reflections

48,703

Completeness (%)

95.3, 91.6

Mean I/σI
b

Rsym%

6.9, 1.4
7.7, 28.0

Refinement statistics
Resolution (Å)

20-1.9

No. protein + ligand atoms

5,358

No. solvent atoms

528

R (%), Rfree (%)

20.6, 25.6

2

2

Wilson B (Å ), Refined <B> (Å )

14.2, 18.4

Rmsd ideal bond lengths (Å)

0.008

Bond angles (°)

1.10

Ramachandran plot statistics
Most favored regions (#,%)
Disallowed regions (#,%)
a

484, 88.8
3, 0.6

b

Highest resolution bin. Rsym = Σ(|Ii-<I>|)/ΣIi. All reflections with I/σI < -1.0 eliminated from scaling.

Enzyme Assays. Inhibitors were assayed against purified hMMP-1 hMMP-2, hMMP-8, hMMP9, and hMMP-13 and MMP-14 using an enzyme assay based on cleavage of the fluorogenic
peptide MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2. Human MMP-3 activity was measured using
a fluorogenic substrate containing glutamic acid and (S)-2-aminopentanoic acid as reported by
Nagase.72 Assay conditions were similar to those described in G. Knight et al.73 All basic
compounds were tested as their hydrochloride salts unless otherwise indicated.

MMP-1 was obtained from MMP-1 expressing transfected HT-1080 cells provided by Dr.
Harold Welgus of Washington University in St. Louis, Mo. The MMP-1 was activated using 4aminophenylmercuric acetate (APMA), and then purified over a hydroxamic acid column.
MMP-2 was obtained from MMP-2 expressing transfected cells provided by Dr. Gregory
Goldberg of Washington University. MMP-9 was obtained from MMP-9 expressing transfected
cells provided by Dr. Gregory Goldberg. The MMP-13 was obtained as a proenzyme from a full-

length cDNA clone using baculovirus, as described by V. A. Luckow.74 The expressed
proenzyme was first purified over a heparin agarose column, and then over a chelating zinc
chloride column. The proenzyme was then activated by APMA for use in the assay. Further
details on baculovirus expression systems have been described by Luckow.75

The enzyme substrate was a methoxycoumarin-containing polypeptide having the following
sequence: MCA-ProLeuGlyLeuDpaAlaArgNH2 where, “MCA” is methoxycoumarin and “Dpa”
is 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl alanine as purchased from Baychem (Redwood
City, Calif.) as product M-1895. Compounds were dissolved at various concentrations using 1%
dimethyl sulfoxide (DMSO) in a buffer containing 100 mM Tris-HCl, 100 mM NaCl, 10 mM
CaCl2 , and 0.05% polyethylene glycol lauryl ether at a pH of 7.5. These solutions were then
compared to a control (which contained equal amount of DMSO/buffer solution, but no
hydroxamate compound) using Microfluor™ White Plates (Dynatech, Chantilly, Va.).
Specifically, The MMPs were activated with APMA or trypsin. Then the various
hydroxamate/DMSO/buffer solutions were incubated in separate plates at room temperature with
the activated MMP and 4 um of the MMP substrate. The control likewise was incubated at room
temperature in separate plates with the MMP and 4 uM of the MMP substrate. In the absence of
inhibitor activity, a fluorogenic peptide was cleaved at the gly-leu peptide bond of the substrate,
separating the highly fluorogenic peptide from a 2,4-dinitrophenyl quencher, resulting in an
increase of fluorescent intensity (excitation at 328 nm/emission at 415). Inhibition was measured
as a reduction in fluorescent intensity as a function of inhibitor concentration using a Perkin
Elmer (Norwalk, Conn.) L550 plate reader. The IC50's were the calculated from these
measurements.

Pharmacokinetic (pk) evaluation of MMP Inhibitors in Rats
Under metofane anesthesia, the femoral artery (all 8 rats) and femoral vein (only 4 of 8 rats) are
isolated and canulated with PESO tubing and secured with 3.0 silk suture. The following
determinations require two catheters, with the venous line being used for infusion of compound
(in the group of rats that receives compound via the intravenous (IV) route.), and the arterial line
being used for collection of blood samples. The rats are then placed in restraining cages that
permit minimal movement and allowed to recover from anesthesia for approximately 30 minutes.
At time 0 (prior to dosing), blood samples (400 µL) are collected from arterial cannula.
One group of rats (4 rats per group) receives compound via the oral route at a dosing volume of 2
mL/kg (10 mg/mL, dissolved in 0.5% methylcellulose, 0.1% Tween® 20), while the other group
of rats receives compound via the intravenous cannula, at a dosing volume of 2 ml/kg (10
mg/mL, dissolved in 10% EtOH, 50% PEG 400, 40% saline). The blood samples are collected
from the arterial cannula at 15, 30, 60, 120, 240, and 360 minutes from the oral group with an
additional 3 minute sample being collected from IV group. After each sample, the cannulas are
flushed with PBS containing 10 units/mL heparin. The animals are subjected to euthanasia with
an excess of anesthesia or carbon monoxide asphyxiation when the study is terminated at 6 hours.
Blood samples from each time point are assayed for MMP-13 enzyme inhibitory activity and the
circulating concentration of compound plus active metabolites is estimated based on the standard
curve. Pharmacokinetic (pk) parameters are calculated by the VAX computer program CSTRIP.

MX1 Tumor Model Method

Mice were implanted subcutaneously with 1 mm3 MX-1 human breast carcinoma fragments in
the flank. Tumors were monitored reached the desired size, approximately 100 mg and then
pair-matched and assigned to treatment groups. The chemotherapy drug Cyclophosphamide
(CY) was obtained as the formulated pharmaceutical drug (Neosar®; Pharmacia). Compound
19w was formulated in MC/TW 80 vehicle (0.5% methyl cellulose: 0.1% polysorbate 80).

CY was administered to mice i.p. on the day of pair-match (Day 1) on a qd x 1 schedule at a dose
of 120 mg/kg. Tumors were monitored until they reached an approximate nadir in size at which
time they were administered oral treatment b.i.d. to end with vehicle or compound 19w at doses
of 50, 25, 12.5 and 6 mg/kg (b.i.d. to end). The test was terminated on Day 90.

The tumor growth delay (TGD) method was used in this study; treatment-effected mean
increases in survival of various groups were compared to each other and to the mean survival
time of breast tumor-bearing mice receiving only vehicle. In the TGD method, each animal was
euthanized as a cancer death when its MX-1 carcinoma reached a size of 1.5 g.

PC3 Tumor Model Method
PC3 tumor cells were grown in F12/MEM (Gibco) and 7 % FBS(Gibco). The cells were
mechanically harvested, washed twice with cold media and resuspended in cold media with 30 %
matrigel (Collaborative Research) and stored on ice. Balb/c nu/ nu at 7- 9 weeks of age were
injected with 3 -5 x 106 cells in the flank of the mouse. Cells were injected in the morning and
dosing started that same evening. The animals were gavaged b.i.d. from evening of day 0 to day
25-30, when the animal were euthanized and tumors weighed. Vehicle and compound 19w

formulated in vehicle (MC/TW 80 vehicle; 0.5% methyl cellulose: 0.1% polysorbate 80). Tumor
measurements begin on day 7 and continue every 3rd to 4th day until the mice were sacrificed.

In some experiments, mice were treated as described above with 19w and treated with a single
dose of cisplatin (10 mg/kg i.p. diluted in PBS) on day 8 post cell injection.

Bovine Nasal Cartilage Degradation Assay

Based on the method described by Bottomley, et al,58 fresh bovine nasal cartilage disks (1 mm
thick x 8 mm in diameter) were sterilely prepared and incubated for 72 hours in DMEM
containing 5% heat-inactivated FBS containing penicillin (100 IU/mL), streptomycin (100
ug/mL) and amphotericin B (0.25 ug/mL). Disks were weighed to insure uniformity, divided
into eighths, plated one piece per well in a 96-well plate, and incubated overnight in the DMEM
plus penicillin/streptomycin/amphotericin B media. Degradation of cartilage explants was
induced by replacing media with fresh media containing cytokine stimulation (DMEM plus
recombinant human IL-1 (10 ng/mL) and oncostatin M (50 ng/mL) ) and various concentrations
of test compound. Cultures were incubated at 37°C/5% CO2 for up to 16 days, collecting
supernatants every 3-4 days and replacing with media containing fresh cytokines and test
compound. Minimally, triplicate incubations were conducted for each condition. Inhibition of
cartilage degradation was measured by quantification of hydroxyproline in the supernatants
collected from explant cultures after hydrolysis with 6N HCl at 110°C for 24 hours. The
presence and amount of hydroxyproline in hydrolysates was measured by mass spectrometry.
Cartilage degradation was calculated as a percentage of the hydroxproline released into the

supernatant collected over the 16 days in the presence of test compound relative to cultures
without added inhibitor.
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Table 1. IC50 values (nM) versus MMPs for α-tetrahydropyranyl sulfones
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MMP7

MMP8

MMP9

MMP13

MMP14

clogPa

Cmax
(ng/mL)

C6h
(ng/mL)

t1/2
(h)

BA
(%)

9a

268

0.1

7.0

-

0.4

0.4

0.1

-

0.80

872

50

1.74

5.8

9b

1800

0.3

18.1

-

1.8

2.9

0.45

4.5

1.51

-

-

-

-

435

<0.1

18.1

-

1.2

0.3

0.15

5.6

1.51

3119

506

1.5

45.8

3600

0.35

35

-

4.0

5.0

0.8

47

2.10

-

-

-

-

9e

400

0.2

-

-

-

<0.1

0.3

1.71

0.13

-

-

-

-

9f

300

<0.1

-

-

-

<0.1

0.1

10.5

1.56

9g

1400

0.1

50

-

2.4

1.7

0.25

20

2.69

-

-

-

-

9h

>10K

0.8,
6.0

55.3

-

30

42.5

0.8

1.3K,
24

1.68

1143

257

1.12

18.3

8000

0.1

22

>10K

9,4

1.2

0.4

64

1.68

4304;
98,500

1154,
8133

nd,
3.68

33.0,
62.1

Cmpd

R2

Cl
9cb

Cl
9d

Cl
OH

CF3
9i

a

9j

1140

<0.1

35

-

0.9

0.2

<0.1

10.6

1.83

8584

1172

1.87

35.9

9k

2500

<0.1

-

-

-

<0.1

<0.1

3.63

1.36

-

-

-

-

9l

5000

0.4

20

-

0.4

0.25

0.25

200

2.47

7272

3113

1.71

49.0

9m

5000

0.6

-

-

-

-

1.0

-

-0.47

1610

3

0.25

42.3

calculated by ACD Labs.

b

Some data for 9c previously reported42

Table 2. IC50 values (nM) and Oral Rat PK Data of α-Piperidine Sulfones (20 mpk suspension)

Cmpd

R1

R2

MMP1

MMP2

MMP3

MMP7

MMP8

MMP9

MMP13

MT1MMP

clogPc

6a

propargyl

-

8660

0.33

13.0

>10K

1.8

1.5

0.40

19.1

19a

propargyl

3600

0.4

0.2

-

10

1.1

0.4

19b

2-pyridylmethyl

4500

0.2

20.6

-

1.9

0.1

1000

0.1

-

-

-

2.04

Cmax
(ng/mL)
13630

C6h
(ng/mL)
281

t1/2
(h)
1.1

BA
(%)
28

-

1.57

27158

192

1.01

36.9

0.3

3.1

1.44

8551

160

-

-

0.2

0.25

6.8

2.00

-

-

-

-

OCH3

OCH3

19c

19db

propargyl

>10K

0.1

32.6

-

1.6

2.0

0.25

90,
17.9

3.08

5312

21

0.73

23.8

19e

methoxyethyl

10K

0.1

-

-

-

-

0.2

-

2.83

-

-

-

-

>10K

1.0

22.5

-

1.8

2.2

2.7

159

3.49

-

-

-

-

2000

0.3

-

-

-

-

0.5

25.8

2.16

-

-

-

-

770

0.1

-

-

-

0.21

0.1

13.3

2.31

-

-

-

-

19f

19g

19h

methoxyethyl

19i

propargyl

>10K

3.3

-

-

-

82.3

2.9

3486

0.01

-

-

-

-

19j

H

4400

0.4

35

-

2.4

3.8

1.9

21.1,
145

0.74

1548

128

-

-

19k

propargyl

2000

0.2

18.1

-

1.3

0.3

0.6

4.2,
25.6

1.62

18,474

134

0.843

30.1

19l

methoxyethyl

2400

0.25

20

-

1.2

0.27

0.2

4.0

1.37

-

-

-

-

19m

1000

0.5

-

-

-

<0.1

0.3

0.73

1.51

13079

206

-

-

19n

6000

0.2

21.5

-

1.5

1.9

0.5

49.4

1.47

9460

15

3.30

16.6

19oc

>10K

0.1

76.8

>10K

1.3

2.3

0.2

500

2.43

8316

631

1.48

36.3

19p

H

>10K

1.7

64.7

-

2.0

4.0

1.2

160

1.66

540

150

1.88

12.4

19q

N-morpholinyl-ethyl

>10K

0.3

-

-

-

0.1

0.35

7.4

1.41

147

73

0.94

2.6

>10K

0.3

40

-

1.4

1.9

5.5

58.6

2.95

5118

429

2.08

48.3

19r

19s

ethyl

>10K

0.2

36.9

-

1.4

1.5

0.6

100.5

2.64

-

-

-

-

19t

methoxyethyl

>10K

0.2

23.9

9000

1.9

0.25

0.2

108

3.08

32938

14078

2.99

34.1

19u

H

10K

<0.1

21.5

-

0.7

0.22

0.1

53.3

1.81

630

223

1.78

6.7

19v

methoxyethyl

>10K

<0.1

28.7

7000

1.7

0.18

<0.1

13

2.44

29634

20521

2.94

67.9

4000

<0.1

22

7000

1.2

0.15

0.1

4.6

2.58

4160

440

2.85

23.0

19w

19x

2-pyridylmethyl

6000

0.2

115

>10K

0.6

0.2

<0.1

4.1

2.54

36810

1850

1.25

46.8

19y

3-pyridylmethyl

4600

<0.1

42.5

>10K

1.5

0.6

0.2

3.7

2.54

52640

1900

1.05

49.8

19z

ethoxyethyl

5900

<0.1

-

-

-

0.1

<0.1

9.5

2.82

3130

3040

1.66

14.7

19aa

hydroxyethyl

4500

<0.1

-

-

-

-

<0.1

-

1.68

1380

570

1.39

21.9

19bb

acetyl

3600

0.1

18.1

-

1.6

0.1

0.2

9.0

0.85

159

72

1.06

4.0

19cc

propargyl

2600

<0.1

-

-

-

<0.1

0.2

1.33

2.68

-

-

-

-

19dd

methyl

>10K

<0.1

-

-

-

0.18

0.6

24.9

2.25

-

-

-

-

>10K

<0.1

-

-

0.4

<0.1

<0.1

7.1

3.09

-

-

-

-

19ee

a

Data for 6 taken from Becker et. al.42 except for MMP-14

b
c

calculated by ACD Labs.

Some hemolysis was observed as evidenced by blood in the urine after iv dosing.

Table 3. Pharmacokinetic Parameters of 19v After a Single Oral Administration of 20 mg/kga
Mouse (M)
Mouse (F)
Rat (M)
Rat (F)
Dog (M)
Dog (F)
Cyno Monkey (M)
a

Tmax (hr)
0.167
0.167
2.00
4.00
0.833 ± 0.167
0.500 ± 0.000
1.67 ± 0.33

blood sampled out to 24 h.

Cmax (µg/mL)
26.6
41.0
42.4
69.8
60.6 ± 5.9
68.9 ± 1.2
37.1 ± 2.9

AUC(0-∞) (hr*µg/mL)
29.3
36.1
273
668
228 ± 41
156 ± 16
191 ± 35

BA (%)
51.7
80.8
66.6
82.2
64.0 ± 6.1
69.2 ± 2.1
53.8 ± 0.7

Table of Contents Graphic

